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 Traditional liposomes degrade into lower-order micelles when PEGylated to even minor degrees 
(6-7 mol%), and thus can offer only limited steric exclusion against opsonization during in vivo delivery. 
Over the past decade, the laboratory of Professor Leaf Huang has pioneered advances in PEGylated 
nanoparticle development under the phenomenon known as the “Supported Bilayer,” extending 
maximal densities out to 20 mol% and observing diverse pharmaceutics phenomena as a result in an 
array of nanoparticle core formulations. However, limitations in circulation longevity, terminal 
biodistribution, and formulation reproducibility and scalability continue to affect the most novel of 
these supported bilayer-based systems. 
 Herein, we extend the supported bilayer phenomenon to its maximal limits in spontaneous self-
assembly, presenting for the first time a liposome coated exclusively by PEGylated phospholipids. 
Utilizing lipid-coated calcium phosphate (CaP) and magnesium phosphate (MgP) as well as pure cisplatin 
(CDDP) cores of diverse sizes (10-40nm) as well as varying PEG chain lengths (350-5000 Da), we 
kinetically trap a relatively monodisperse nanoparticle population through simple solvent mixing in thin 
film rehydration, a process which is insufficient for non-exclusively PEGylated LCP suspension. Ex vivo 
experimentation highlights the ability for such formulations, particularly at increasing PEG chain lengths, 
to effectively screen nanoparticle surface charge and thus limit protein adsorption onto the nanoparticle 
and uptake of the nanoparticle into mononuclear phagocytes. Further, ratiometric characterization of 
the nanoparticle at a number of radial surfaces exposes the extremely high density of PEGylation which 
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such nanoparticles can support, underscoring not only the equivalent lipid density to that of a traditional 
liposome bilayer, but the importance as well of aspect ratio in properly contextualizing the limits of 
spontaneous self-assembly. 
 Such fully-PEGylated (PCP, PMP, PPC as formulations employing calcium, magnesium, or 
platinum, respectively, within the nanoprecipitate core) liposomes allow us to explore a variety of 
hypotheses related to PEGylation density on a spontaneously self-assembled liposome surface for the 
first time. For instance, PCP exhibit a PEG chain length-dependent circulation longevity and robust 
immune evasion while resolving the rapid distribution clearance observed with the traditional LCP 
formulation and enhancing nanoparticle cellular internalization in commonly employed strategies of 
receptor-ligand targeting. Such liposomes advance the platforms’ pharmaceutics properties both locally 
and systemically as well, facilitating both strong accumulation within solid tumors upon intravenous 
injection and a more rapid and extensive lymphatic drainage upon subcutaneous administration. Finally, 
when coupled with potent mechanisms of drug release, these fully-PEGylated liposomes reveal potent 
and competitive therapeutic activity in areas ranging from cancer chemotherapy to immune activation 
while limiting systemic toxicity overall. Thus, given the competitive flexibility and functionality of fully-
PEGylated liposome formulations through a maximally-supported lipid bilayer, we anticipate continued 
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CHAPTER 1: CURRENT AND FUTURE METHODS AND APPLICATIONS RELATED TO LIPOSOME 
DEVELOPMENT AND THE SUPPORTED BILAYER PHENOMENON 
1.1: Summary 
 Though traditional liposomal formulations have led to important clinical successes (e.g. Doxil), 
their formulation is foundationally limited in scope. To advance alternative and macromolecularly-
complex therapeutics, novel formulation strategies will be required. A foundational context for such 
delivery lies in the supported-bilayer liposome, which defies conventional physico-chemical lipid 
organization based on intrinsic curvature to create whole new categories of nanoparticle architectures. 
Such liposomes facilitate not only the encapsulation of novel therapeutic agents, but also a notably 
increased surface modification with polyethylene glycol, the most well-known agent of steric exclusion 
against protein adsorption and immune recognition in the entire field of nanoparticle-based drug 
delivery. Such formulations have supported diverse novel therapeutic and pharmaceutic effects in vivo, 
and though they are limited in performance in a variety of key areas, such limitations form the basis of 
the novel work to come in later chapters. Further, as we move forward in the interface between 
formulation science and general biology, careful understanding of the capabilities of the former will 
greatly improve efforts to overcome the barriers posed by the latter. 
1.2: Introduction to Traditional Liposome Formulation 
 Liposomes represent a class of colloidal nanoparticles comprised of a lamellar lipid bilayer 
structure in solution surrounding an aqueous core. Such a physicochemical phenomenon is driven most 
obviously by the amphiphilicity of the lipid molecules which form the bilayer, but also in the intrinsic 
lipid curvature which each lipid molecule possesses in colloidal suspension – a physical representation of 
the driving forces behind the thermodynamic process of emulsification. Breaking down lipid molecules 
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into their common component parts (the polar and often charged “headgroups” as well as their acyl 
chain[s]), we can gain an appreciation for the types of colloidal organizations we can expect in various 
solutions, and define expectations for the formulations which will be expounded upon in later sections. 
Lipids which possess headgroups of a cross-sectional area (CSA) in excess of that of their acyl chain(s) 
are often referred to as “positive-curvature” lipids, forming micelles in aqueous solution, while the 
converse of predominant acyl chain-based CSA will drive reverse-micellar organization in a suitable 
organic solvent. Examples of the former and latter, respectively, are phosphatidylinositol and 
diacylglycerol. Diacyl phosphatidylcholine-based lipids, however, lack a meaningful intrinsic curvature, 
and upon introduction into an aqueous environment will spontaneously organize into lamella, the basis 
of a liposomal bilayer (Figure 1.1).1 As a logical extension, combinations of lipids in varying proportions 
can yield net-positive, net-negative, or net-zero curvature colloidal organizations which will form the 
previously described micellar or lamellar phases in solution as well. It is important to note here the 
spontaneous nature of this self-assembly, in that it remains impossible without chemical or physical 
intervention to produce phases out of concert with the nature of the lipid curvature of the system at 
hand, though a variety of efforts have been made at intervening in such ways for controlled drug 
delivery and release.2-4 
 Formulation of liposomes can progress from a variety of methods, including but not limited to 
solution-based phase transition such as dispersion and solvent displacement;5 physical agitation such as 
vortexing and sonication;6 thermodynamic influence such as compression and freeze-thaw cycling;7 and 
highly controlled processes such as membrane extrusion8 and microfluidic mixing.9 Each can possess an 
array of benefits and limitations based not only on the desired liposome structure, but on the 
therapeutic cargo to be encapsulated as well, and a combination of these and other methods may be 
employed in the full liposome formulation process.10, 11 Both bilayer and core can be exploited for drug 
encapsulation and therapeutic delivery, though the latter has received the majority of attention in this 
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regard due to the protective nature the bilayer provides to core-encapsulated components, the risk of 
uncontrolled release from bilayer-encapsulated therapeutics, and the extraordinarily low loading 
capacity (in terms of total particle volume) and structural complexity required for effective hydrophobic 
drug delivery through liposomes as opposed to micelles.6, 12 Given the diversity and complexity of such 
considerations, a rational formulation process design for each drug molecule, related to the specific 
delivery needs which must be engineered into the nanoparticle system, remains vital to effective 
therapeutic development. 
1.3: Liposome PEGylation: Physicochemical Characteristics 
 Of the advances made upon liposomal platforms for drug and gene delivery over the last half-
century, surface PEGylation arguably represents the foundational achievement toward clinically-
meaningful effects.13, 14 Polyethylene glycol, or PEG, incorporated on the surface of liposomes for the 
first time over a quarter-century ago,13 is an unconventional polymeric material in that it is highly polar 
yet possesses neither ionic moieties nor hydrogen bond donors, facilitating extraordinary solubility in 
both water and a variety of polar-organic solvents. Thus, when conjugated at the polar headgroup to 
lipid molecules, PEGylated lipids can exploit both organic phase solubility and aqueous phase 
amphiphilicity to functionalize a variety of nanoformulations including micelles and liposomes.6, 12 Across 
such systems, inclusion of PEG as a surface coating to such nanocarriers has facilitated profound 
extensions in nanoparticle circulation longevity in vivo as well as in the clinic.15 
 Functionally, the conformational flexibility and non-ionic nature of PEG serves to modify the 
nanoparticle surface as a steric exclusion barrier,16 minimizing aggregation in formulation and stabilizing 
and neutralizing the particle surface in the aqueous phase, and dramatically reducing the rate of protein 
adsorption to the particle surface when exposed to biological media. Transit within the host upon 
injection to the intended site of action exposes nanoparticles to an onslaught of biomaterials, including 
but not limited to antibodies, complement, albumin, and lipoproteins which can accumulate on the 
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nanoparticle surface and either directly represent a condition of “non-self” to the host immune system, 
or facilitate aggregation which can intensify such host recognition and elimination of these 
nanoparticles. A PEGylated nanoparticle surface represents a rapidly evolving set of conformational 
states of each PEG chain local to its conjugation site, creating a corona-like conformational cloud in such 
areas which is relatively inert in its chemical interactions with components of biological media, and can 
disrupt sterically the physical interactions between the nanoparticle surface and such components. 
Therefore, a sufficiently-PEGylated nanoparticle injected intravenously into the systemic circulation may 
represent a relatively biologically inert system that can evade immune recognition and clearance in 
order to enhance its distribution (and that of its therapeutic cargo) to the intended site of action. It is 
valuable to note as well that “not every non-ionic hydrophilic polymer can provide stealth behavior” – 
control over polymer molecular weight and polydispersity can be essential in conferring an effective 
steric barrier.15 
 Liposome modification with PEG has been shown to expand liposome circulation longevity to 
allow a relevant exploitation of the enhanced permeability and retention (EPR) effect, a phenomenon 
whereby nanoparticles can extravasate through porous neovasculature and accumulate over time at 
that site due to poorly-developed mechanisms for lymphatic drainage, for delivery to solid tumors.6, 16 
However, due to strong surfactant forces directed upon a PEGylated liposome surface, further 
compounded by the relatively weak hydrophobic exclusion effect which supports formation of a lipid 
bilayer around an aqueous core, PEGylation at greater than roughly 6-7 mol% lipids serves to dissolve 
the lipid bilayer structure, producing lower-order micelles which possess more thermodynamically-
stable hydrophobic cores (Figure 1.2, “DOTAP liposome”).17 The principles of intrinsic lipid curvature 
inform these findings as well, with PEG conjugates at the lipid headgroup representing an extreme case 
of natural CSA excesses compared to lipid acyl chains. Inclusion of even a small proportion of PEG-lipid 
on the liposome surface serves to dominate the net curvature of that surface, driving the system as a 
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whole to approach a new thermodynamically-stable state. Therefore, under conditions of spontaneous 
self-assembly, it remains impossible to include greater proportions of PEG on the liposome surface 
without compromising the surface itself of the properties which govern its stability. 
1.4: Clinical Application of Traditional Liposomes 
 Despite such limitations in PEGylation density, traditional liposome formulations have shown 
considerable clinical successes. A classic comparison between Doxil, a PEGylated liposomal formulation 
of the anticancer drug doxorubicin, and Myocet, the un-PEGylated analogue of such a formulation, 
highlights the clinical value of PEGylation along with and beyond the function of the free drug (it should 
be noted that, unlike Doxil, Myocet is only approved for clinical use outside of the US). Both liposomal 
formulations of doxorubicin employ a creative strategy for drug loading within the aqueous nanoparticle 
core by establishing a pH gradient across the lipid bilayer, whereby through simple diffusion and 
ionization, doxorubicin can become entrapped within the core at extremely high loading capacities (LC, 
the ratio of drug weight to total particle weight).18 However, the inclusion of PEGylation within the 
formulation dramatically alters the distribution profile of both nanoparticle and drug upon 
administration. Unlike Myocet, Doxil avoids rapid clearance from the circulation and can serve as a 
therapeutic depot over its distributive course through the host, avoiding the immune suppression 
inherent to the accumulation of Myocet within scavenging cell populations of the mononuclear 
phagocyte (MPS) system, as well as the cardiotoxicity observed with free doxorubicin administration (a 
Cmax-related response which can be avoided through continuous, long-circulating release from a lipid 
nanoparticle) in favor of a peripheral edematous toxicity known as palmar-plantar erythrodysesthesia 
which is largely preferable in comparison.14, 19 Thus, in combination with an exploitation of the EPR 
effect for functional drug distribution to solid tumors, the PEGylated formulation Doxil has gained broad 
approval for clinical use as a second-line therapy in conditions such as ovarian cancer, AIDS-related 
Kaposi’s sarcoma, and multiple myeloma. 
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 Despite such successes, the “Doxil model” for formulation development lacks broad potential 
across a wide variety of therapeutic and diagnostic capabilities. We will discuss formulations which 
support such efforts in later sections. 
1.5: Common Alternatives to Liposome PEGylation 
 Despite its strong capabilities, PEG as a biomaterial is not without meaningful limitations, 
including but not limited to unexplained complement-induced hypersensitivity reactions, PEG-specific 
antibody responses and an accelerated blood clearance upon subsequent injections, and a lack of 
biocompatible degradability. With these considerations in mind, a variety of alternative polymer 
systems have been explored, including poly(amino acid)s, polyglycerols, polyacrylamides, and poly(ethyl 
oxazoline)s, each of which can resolve one or more of the issues in formulation performance described 
above.15 However, the exact mechanism and extent of these considerations are still subject to scientific 
inquiry, with the overall utility, flexibility in application, and commercial availability of PEG maintaining 
its broad application both preclinically and clinically. 
1.6: Dense PEGylation and the Supported Bilayer Phenomenon 
 Though PEGylation at the liposome surface can establish a local area of steric exclusion at the 
lipid conjugation site, overall steric exclusion at the level of the liposome requires a more thorough 
physical characterization. As might be expected, the conformation of PEG on a surface is actually a 
function of the grafting density. As two PEG chains become sufficiently close to one another, their ability 
to explore the conformational space surrounding themselves becomes impeded by the other chain (the 
radius at which this is expected to occur is known as the Flory radius [RF], equal to the product of the 
monomer persistence length a and the three-fifths power of the number of monomers N which 
comprise the polymer [=aN3/5]).20 As multiple chains begin to impede each others’ conformational 
exploration, or put another way, as the free volume available to each chain at the nanoparticle surface 
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begins to shrink, the polymer chains are forced to explore conformations extended outward radially 
from the nanoparticle to a far greater frequency than would be expected on a typical “random walk.” 
This increased presence of polymer coatings at a more radially outward extension per unit time is known 
colloquially as the transition from a “mushroom” conformation to a “brush” conformation (Figure 1.3).21 
In a brush-like state, stealth polymer coatings on a nanoparticle surface are more capable to exclude 
sterically due both to the increased density of polymers at the nanoparticle surface and the chain 
length-dependent extension of the polymers from that surface, creating a more dense conformational 
cloud than would be possible through one chain in its own local area. 
 It is known that a PEGylated planar surface would begin such a transition at roughly 5 mol% lipid 
PEGylation.6 Therefore, means by which to PEGylate a liposome to a much greater degree would be 
greatly desired, despite a seeming physicochemical incapability of doing so spontaneously. Nearly a 
decade ago, the first work was published on what is known as the “supported bilayer” phenomenon, 
built out of a nanoparticle system referred to as liposome-polycation-DNA, or LPD (Figure 1.2), a 
nanoparticle which instead of an aqueous core possessed a precipitated polyion-based core material. 
While it was shown easily that DOTAP liposomes, co-formulated with 10 mol% PEGylated lipids of the 
total lipid content, degraded into lower-order micellar structures, DOTAP LPD at the same PEG 
proportion remained stable, capable of delivering high proportions of injected siRNA dose to tumor.17 
Over the past decade, our perspective on the supported bilayer phenomenon has evolved and refined 
itself, and can largely be described in three requirements of the core material: “solid, stable, and 
chemically interactive.” As a solid core rather than an aqueous phase for the liposome, the lipid bilayer 
is now presented with a potential means for physical resistance to bilayer collapse under increasing 
PEGylation density, while a stable core remains self-evident to maintaining bilayer integrity under such 
conditions. However, broad chemical interaction between the bilayer (in particular, the inner leaflet) 
and the core is essential to conferring support, as a core which can freely dissociate from the lipid 
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bilayer, however solid and stable it may be, will elicit collapse of the free bilayer under high PEG 
conditions. Therefore, all three conditions must be met in order to satisfy the criteria of a supported 
bilayer. 
1.7: Polyanion Complexes as a Supported Bilayer Platform 
 Over the past decade, our lab has expanded the polyion-complex supported bilayer into a wide 
variety of biomaterials applications, including novel therapeutic22 and degradable23 polymers for drug 
and gene delivery. However, the formulation process has remained largely consistent over time, 
beginning with a complexation of anion (DNA, hyaluronan, or etc.) with cation (protamine, PEI, or etc.) 
to produce a polyion complex which is net-negatively potentiated in aqueous solution. Control of 
surface potential is essential for bilayer support (Figure 1.4), as cationic DOTAP is introduced to create 
two concentric bilayers surrounding the polyion core: one supported at the core surface, and one 
unsupported. Introduction of PEG micelles into the system serves to degrade the unsupported bilayer, 
but leaves the supported bilayer intact, capable of supporting close to 11 mol% PEGylated lipids on the 
outer liposome leaflet.17 Such nanoparticles can be purified further via density gradient centrifugation as 
well, in order to properly characterize such physicochemical phenomena. 
1.8: Nanoprecipitates as a Supported Bilayer Platform 
 In the last five years, our lab has expanded supported bilayer nanoparticle formulation with an 
entirely new platform known as the lipid-coated nanoprecipitate, the most extensively researched of 
which is referred to as liposome-calcium-phosphate, or LCP. Built off of an acid-sensitive calcium 
phosphate core, known for decades to be effective in mediating endosome escape within cells by means 
of osmotic bursting,24 LCP can encapsulate a variety of materials from heavy metals25 to RNA/DNA 
vectors,26 proteins and peptides,27 and phosphorylated pro-drugs.28 LCP can be uniquely formulated with 
an entirely asymmetric lipid bilayer as well through a two-step process, allowing for nearly limitless 
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capacity for functionalization of the lipids on the outer bilayer leaflet to suit the needs of any 
application.29 Figure 1.5 exhibits a cartoon of such a multifunctional nanoparticle, encapsulating 
oligonucleotides herein, along with a transmission electron microscopy (TEM) image of the calcium 
phosphate core, which can be observed without staining. Given the small size of such nanoparticles 
(yielding a decrease in steric hindrance in insertion), PEGylation also can be enhanced on such a 
supported-bilayer nanoparticle system, up to 20 mol% of the outer leaflet.30 
 Though an exceedingly capable nanoparticle system, as shown in later sections, formulation of 
LCP involves a multi-step process of nanoprecipitation and lipid monolayer coating, purification and thin 
film preparation, and rehydration in aqueous suspension (Figure 1.6). To begin, two separate water-in-
oil microemulsions are prepared, comprised of Igepal-co-520, a strong non-ionic surfactant, and 
cyclohexane as the phase in excess. To one emulsion, the drug of interest is dissolved in molar 
concentrations of calcium chloride, while the other emulsion contains millimolar concentrations of 
ammonium hydrogen phosphate. After effective dispersion of the aqueous phases as nano-droplets, the 
emulsions are mixed together to precipitate the calcium phosphate nanoparticle cores, and the 
phosphate-bearing lipid DOPA is added to co-precipitate as a monolayer on the nanoparticle surface, 
creating an intermediate product of a DOPA-coated calcium phosphate (CaP) core which encapsulates 
the drug of interest. Precipitation in ethanol and purification in chloroform allow for thin film 
preparation of the CaP cores with the outer leaflet lipids of interest, where after aqueous resuspension 
under vortexing and sonication the final product, LCP, is formed. LCP is also amenable to density 
gradient centrifugation for further purification and characterization as well. 
 Despite an improved endosome escape capability of therapeutics driven by calcium phosphate 
nanoprecipitate dissolution,29 a notable drawback of the LCP system is its relatively low loading capacity, 
ranging between 1-10% for therapeutic applications. More recently, an alternative supported bilayer 
nanoprecipitate platform was developed wherein, instead of calcium phosphate, pure cisplatin was 
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utilized, exploiting the characteristic solubility of potassium chloride and the cisplatin precursor 
Pt(NH2)2(H2O)2 within the same microemulsion-based formulation process (though in this conception, 
including DOPA within the cisplatin precursor microemulsion phase prior to emulsion mixing). The final 
product, referred to as liposome-platinum-chloride, or LPC, represents the same structural features of 
the LCP particle system but, given that the core is comprised of pure drug, possesses a loading capacity 
upwards of 80% by weight. Such particles degrade slowly over time (though on the order of hours, given 
their high surface area to volume ratio), but exhibit no burst release of cisplatin, allowing for strong 
application of nanoparticle-based delivery strategies in vivo as well.31 
1.9: Therapeutic Advances Made Through Supported Bilayer Nanoprecipitates 
 Both LCP and LPC have been foundational toward increasing not only the capabilities of our lab 
in therapeutic development and application, but also in defining our understanding of the biological 
systems we aim to treat and the barriers associated to drug delivery in general. While discussion of each 
and every advance would be exceedingly inefficient herein, a number of studies related to LCP delivery 
to the liver and LPC delivery to solid tumors remain foundational to the work which follows. 
 Conventional wisdom dictates that nanoparticle accumulation within the liver is a predominant 
function of professional phagocytic cells, such as Kupffer cells, which serve to scavenge and clear foreign 
matter from the circulation.6 However, when PEGylated to exceedingly high degrees (upward of 10-15 
mol%), it has been observed that LCP exhibits a spontaneous shift in tropism toward uptake by the 
primary hepatocytes. When un-PEGylated or PEGylated to minor degrees, LCP encapsulating fluorescent 
oligonucleotides can be observed in liver tissue sections (Figure 1.7) as accumulating in local “hot spots,” 
a hallmark characteristic of Kupffer cell uptake, whereas increased PEGylation up to 20 mol% facilitates 
broad uptake within hepatocytes and a diffuse fluorescence distribution within the cells.30 Such strong 
distribution to hepatic primary cells has led directly to work on hepatic gene transfer, wherein co-
formulation of plasmid DNA (pDNA) with the cationic peptide CR8C (or CR8C), either linear or disulfide-
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linked, has shown surprisingly high levels of transgene expression for a non-viral vector, reaching levels 
only 100-fold less than the most effective method, hydrodynamic injection (but 100-fold greater than in 
delivering pDNA alone), through an enhanced localization of pDNA within the nucleus (Figure 1.8).26 
Current work (unpublished) suggests that such cationic peptides assist in nuclear translocation through 
an importin-dependent mechanism; in all, hepatic delivery has shown to be one of the most influential 
avenues for progression of LCP development. 
 Within these contexts of transgene expression in the liver and chemotherapy in solid tumors, 
our lab has also focused therapeutic development extensively within the context of eliciting bystander 
effects beyond the target cells of nanoparticle uptake. The clearest example of such efforts comes in the 
form of platinum chemotherapy with the LPC platform, which was shown to elicit high degrees of 
apoptosis within tumors through a subsequent release of platinum from the primary cells of 
nanoparticle uptake. Staining for both particle and either TUNEL or CDDP-DNA adduct formation, a clear 
exponential decay in a nearest-neighbor analysis strongly suggests such post-uptake release of platinum 
and bystander toxicity to surrounding tumor cells (Figure 1.9).31 Thus, the primary means of toxicity for 
such platinum-based therapeutics may not lie within direct cell killing, but within potent off-target 
effects. 
1.10: Original Research: Limitations of Supported Bilayer Nanoprecipitates 
 Despite such foundational advances borne from supported bilayer nanoprecipitate-based 
delivery systems, serious concerns remain relating to their performance both in formulation and in vivo. 
To tackle the latter first, the successes of LCP as a hepatic transgene delivery system mask the overall 
poor circulation longevity of the platform across a number of therapeutic modalities.26, 28, 30 In particular, 
when delivering considerable proportions of nanoparticle or cargo such as with nucleic acid-based 
therapies, previous work has shown roughly 90% of the injected dose to be eliminated within the first 
five hours of circulation, whether or not active targeting has been employed. Under these conditions, 
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nanoparticle clearance is mediated predominantly through the liver and spleen, the latter of which can 
reach exposures upward of 400% ID/g (Figure 1.10). Kinetic analysis reveals further such limitations, 
driven by considerable distribution clearance rates on the order of minutes and elimination clearance 
rates which only moderately salvage the formulation’s circulation longevity (Table 1.1).26 
 Such results extend from recent research stratifying immune cell uptake by both PEG density 
and molecular weight on a polymeric nanoparticle surface, suggesting that true immune evasive 
properties occur at densities which substantially exceed the minimum requirements for brush 
conformation and offering an extended descriptor known as “dense brush” which is nearly three-fold 
smaller than that characterized by RF (Figure 1.3).
21 Though one can appreciate the simplicity of the 
definition of the dense brush transition threshold (RF/D > 2.8, where D represents the average grafting 
distance between PEG polymer chains), it helps to critically examine the data before moving forward, in 
particular since such context will be of great value in framing the data presented in later chapters. The 
data in Figure 1.3 seem to represent that a less stringent Flory ratio (RF/D) falling between 2 and 2.5 
could more effectively represent conditions of stealth when paired with a threshold level of PEG density 
at approximately 0.2 PEG chains per nm2, in particular given that PEG5000 modification at roughly 0.15 
PEG chains per nm2 was entirely ineffective at preventing immune cell uptake, despite falling within the 
dense brush domain as defined previously (the authors go into deep discussion of these limitations as 
well). The authors extend this consideration in separate experiments as well, establishing a threshold of 
0.8 PEG chains per nm2 as sufficient for suppressed particle uptake by immune cells over 24 hours, a 
reasonable time course to observe in vivo for long-circulating effects of nanoparticle coatings.21 
Therefore, while we will make reference to Figure 1.3 on a comparative basis in later chapters, it is 
useful to note the flexibility of definitions for a sufficiently dense brush conformation of PEG which 
could be had. 
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 Further, such issues of performance in vivo stem from a broader challenge in effective 
nanoparticle formulation which continues to plague the LCP platform. Over the past five years, through 
countless method evaluations by dozens of lab members (including myself), the most reliable means 
through which to formulate the complete LCP nanoparticle remains through thin film rehydration 
(Figure 1.11). As is obvious to those experienced in the method, when working with a film of individual 
lipid molecules, exposure to an aqueous phase will not in and of itself yield the traditional 
conceptualization of a liposome, the small unilamellar vesicle (SUV). Rather, heterogeneous suspensions 
of multilamellar structures are formed, and only resolve themselves into SUVs through post-
resuspension processing through any selection of chemical or physical methods (outlined in Section 1.2). 
Such methods are notoriously formulation-dependent and in many cases (such as sonication) lack broad 
scalability and/or reproducibility, relegating the use to bench-top, proof-of-concept laboratory studies 
rather than a reliable path to translation. However, in the case of LCP, the formulation demands not 
simply a spontaneous self-assembly of individual lipids into a unilamellar structure, but rather a coating 
of thousands of lipids upon a pre-formed CaP nanoparticle surface. Such demands are of a much greater 
thermodynamic intensity, and the likelihood in any case of thin film resuspension is that a great 
proportion of CaP cores will aggregate irreversibly. Therefore, means by which to resuspend CaP cores 
to a relatively narrow dispersity without physical means of limited scalability would be highly desirable 
for the LCP formulation. 
1.11: Future Directions for Supported Bilayer-Based Liposomes 
 The supported-bilayer nanoprecipitate platform has emerged as a leading mechanism for drug 
encapsulation of a wide variety of kinds while supporting an attractive release profile upon reaching the 
intended site of action. However, efforts by which to scale such a formulation may depend upon its 
ability to be composed under aqueous conditions rather than the reverse microemulsion process 
outlined herein. Further, while delivery in a variety of contexts has shown great promise, the 
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penetrative capabilities of nanoparticles in general, particularly within more clinically-representative 
solid tumor models, has been recently brought into question;32 in these capacities, formulations which 
engender themselves to bystander effect capabilities (such as LCP and LPC) hold great promise in 
advancing the battle against such complex diseases. Combating such disease will invariably require deep 
collaboration between formulation, function, and the underlying biology as well, and the more capable 
scientists are at evaluating the scope of the biological barriers to effective delivery and therapy in 
general, the better equipped the field will be to tackle such challenges. 
1.12: Re-Emphasizing the Perils of Optical Imaging in Biodistributive Analysis 
 The use of fluorescent or luminescent enzymes or proteins in quantitative biochemical 
characterization is one of the most extensive assay bases within all of biomedical science. In the 
following sections, however, particularly those which cater heavily to the kinetic and distributive profiles 
of the nanoparticles in question, the reader will notice a predominant use of radionuclides as the means 
of characterization in this regard, and with good reason. High degrees of tissue autofluorescence are 
known to impede true quantitative analysis; as such, the field has progressed toward the use of far-red 
probes which are less subject to such issues.33 However, fluorescence quenching by blood within whole 
organs, even after perfusion, is less frequently discussed, though previous work has shown it to be an 
extensive attenuator in its own right, with nuclide-based distributive methods most effectively 
representing that of encapsulated drug by comparison.34 Thus, the nuclide-based distribution profiles 
which form the foundation of nanoparticle characterization herein were selected in part to avoid such 
issues, as nuclides of a sufficient emission path length will avoid meaningful impedance by biological 
matter, allowing for cross-tissue comparisons which are not reasonable through fluorescence-based 





 The solid, stable, and chemically interactive cores which serve as the foundation of the 
supported bilayer have opened up entirely new platforms for nanoparticle development which expand 
beyond the physical and chemical limits posed by intrinsic lipid curvature. Though such formulations 
have shown great flexibility in drug encapsulation, development, and delivery, limitations in circulation 
longevity and a dependence upon physical resuspension methods persist. In the next chapter, an 
entirely novel surface coating for liposomal formulations will be presented which overcomes such 
limitations. This novel coating, referred to as full PEGylation (or, as a three-letter nanoparticle acronym 
which our lab is fond of, replacing the first “L” with “P” in each discussed case), will be explored under a 
variety of formulation conditions, characterized for its ability to represent liposomal degrees of lipid 
packing density, and basic pharmaceutics and performance properties in vitro. In later chapters, the 
formulation will be expanded into both local and systemic delivery, where it exhibits entirely new 
distributive phenomena for the supported bilayer platform as well as meaningful therapeutic 
performance in vivo. However, the foundations discussed in this previous chapter will remain 














Figure 1.1: Intrinsic Lipid Curvature Drives Overall Macromolecular Organization. Lipids with 
headgroup CSA in excess of that of its acyl chain(s) are referred to as positive-curvature (+) lipids, with 
the reverse being negative-curvature (-); both form their corresponding micelles under contingent 
solvent conditions. Certain zero-curvature lipids (0) will instead organize into relatively planar 















Figure 1.2: Disintegration of Traditional Liposomes into Micelles under a Strong PEG Surfactant. 
DOTAP Liposomes were formulated either with or without 10 mol% DSPE-PEG, and characterized by 
negative staining through transmission electron microscopy (TEM). By comparison, liposomes which 
possess a polycation-polyanion core complex (LPD) maintain a bilayer structure under relatable 










Figure 1.3: Immune-Evasive Surfaces Require Considerably More PEGylation than Previously 
Anticipated. Polystyrene nanoparticle beads were covalently surface-modified with PEG at various 
densities and molecular weights (x and y axes, respectively) and explored in vitro for immune cell 
uptake. Dashed and dotted lines convey the mushroom-to-brush and brush-to-dense-brush interfaces, 









Figure 1.4: The Supported Bilayer Phenomenon. While traditional liposomes possess an aqueous core 
environment, replacement contextually with a 1) solid, 2) kinetically stable, and 3) chemically 
interactive (with respect to the bilayer) core material competes against micellar driving forces which 















Figure 1.5: Liposome Calcium Phosphate (LCP) as a Multifunctional Nanocarrier. LCP builds a off of 
emulsion-based calcium phosphate (CaP) formulation processes to advance such particles’ utility in 
vivo. (A) LCP possesses an acid-sensitive CaP core which can encapsulate a variety of materials (heavy 
metals, RNA/DNA vectors, proteins/peptides, and phosphorylated pro-drugs) and an asymmetric lipid 
bilayer which allows for broad functionalization on the outer leaflet surface. (B) CaP cores of LCP are 















Figure 1.6: (Scheme) LCP Formulation via Reverse Microemulsion Mixing and Thin Film Hydration. 















Figure 1.7: Spontaneous Alteration of LCP Tropism Toward Hepatocytes under Increasing PEGylation 
Density. (A) LCP-DOTAP NPs and (B) LCP-DOPC NPs encapsulating Texas Red-labeled oligonucleotides 
and coated at varying PEGylation densities were i.v. injected into C57BL/6 mice, after which livers 
were harvested for cryosectioning and staining. As PEGylation density increases beyond 10 mol% to 
20 mol%, nanoparticle uptake shifts to the hepatocytes (diffuse red) over Kupffer cells (arrows). 
Endosome escape is also observed without cationic lipid in formulation. DAPI: nuclei; Alexa 488: 
phalloidin; Texas Red: oligonucleotides. Percentages indicate amount of PEG-DSPE2000 incorporated in 





Figure 1.8: Intracellular Cy3-DNA Fluorescence Distribution in Liver Tissues. C57BL/6 mice were 
treated with LCP-(Control DNA)-Gal, LCP-(Cy3-DNA)-Gal, LCP-(Cy3-DNA+mc-CR8C)-Gal, LCP-(Cy3-
DNA+l-CR8C)-Gal, and hydrodynamic (HD) injection. Images were acquired after cryosectioning of 
livers harvested 6 h after injection. Top images are fluorescence overlay of red from Cy3-DNA, blue 
from DAPI-stained nuclei, and green from FITC-labeled Phalloidin-stained actin; bottom images are 
Cy3-DNA fluorescence only. Inset images are an increased magnification, to better illustrate 
intranuclear Cy3-DNA fluorescence. Monocyclic abbreviated to mc, linear abbreviated to l. Scale bar: 













Figure 1.9: (A-C) Bystander toxicity (TUNEL) driven by cisplatin NP accumulation (Di-I) as a function of 
distance (µm) from initial cell of NP uptake. (D-F) Bystander toxicity (CDDP-DNA adduct immune 
fluorescence) driven by cisplatin NP accumulation (Di-I) as a function of distance (µm) from initial cell 
of NP uptake. Exponential decay of both apoptotic and adduct formation signals as a function of 
distance from Di-I-positive cells, coupled with nearly all cells being double-positive (Di-I and either 
TUNEL or adduct) when identifying the nearest Di-I-positive neighbor to any TUNEL or adduct signal, 
conveys the following: as cells undergo apoptosis due to CDDP-DNA adduct formation from initial NP 
uptake, such cells can subsequently release cisplatin into the neighboring microenvironment, wherein 
bystander cisplatin toxicity can then occur as a function of local cisplatin concentration (i.e. distance 









Figure 1.10: LCP can be Rapidly Cleared by Liver and Spleen as Nanoparticle Dose Increases. Mice were 
administered LCP encapsulating trace 111In via tail vein, with blood sampled serially (A) for circulation 
kinetics and organs harvested (B) for biodistribution (assayed by gamma count). Roughly 90% of the 
injected dose has left the circulation after 5 hours, accumulating within the liver and spleen to 
















CLdist (mL/h) Vblood (mL) t1/2
dist (h) t1/2
elim (h) 
LCP-GAL 4.71 ± 0.22 4.16 ± 0.04 0.6 6.8 
LCP 0.35 ± 0.15 1.24 ± 0.06 2.5 5.8 
 
Table 1.1: LCP Formulated for Gene Delivery Shows Limited Kinetic Longevity In Vivo. Data are 
reported as estimate ± standard error. CLdist = distribution clearance; Vblood = volume of distribution in 
the circulation compartment; t1/2
dist = distribution-phase half-life (estimated as Ln(2)Vblood/CLdist, 
assuming unidirectional initial distribution from the circulation compartment to the peripheral 
compartment; t1/2
elim = elimination-phase half-life (estimated from a linearization of the terminal 














Figure 1.11: Thin Film Rehydration and Applications under LCP. Lipids and/or nanoparticles dried into 
a lipid film can be dispersed into solution to form an array of vesicular structures. Physical methods 
such as vortexing, sonication, and extrusion are often used thereafter to create monodisperse 
populations of small unilamellar vesicles (SUVs). LCP, however, employs a pre-formed nanoparticle 
core to be resuspended, requiring thousands of lipids to act in concert to coat a monodisperse 
population of nanoparticle cores. Further, lipids such as DOTAP and DOPC offer limited steric 






CHAPTER 2: FULLY-PEGYLATED LIPOSOMES (PCP, PPC): 
CHARACTERIZATION AND EX-VIVO PERFORMANCE 
2.1: Summary 
 Traditional liposomes degrade into lower-order micelles when PEGylated to even minor degrees 
(6-7 mol%), and thus can offer only limited steric exclusion against opsonization during in vivo delivery. 
In this work, we present for the first time liposomes coated exclusively by PEGylated phospholipids, 
utilizing lipid-coated calcium phosphate (CaP) and cisplatin (Pt) cores of diverse sizes (10-40nm) as well 
as varying PEG chain lengths (350-5000 Da). Fully-PEGylated LCP liposomes (PCP) show a chain length-
dependent reduction of protein adsorption which couples with grafted PEG chain density to support 
evasion of uptake by peripheral blood mononuclear cells (PBMC), while remaining amenable to active 
targeting strategies which facilitate improved degrees of nanoparticle uptake and meaningful endosome 
escape. Further, such exclusively PEG2000-modified nanoparticles represent an outer leaflet lipid surface 
density commensurate with the formation of a lipid bilayer as well as a PEGylation density which 
interfaces at a “dense brush” conformation, avoid use of scale-limited physical resuspension methods, 
and mediate comparable therapeutic activity in vitro to advanced nanoparticle formulations. We expect 
such improved delivery properties to translate into improved therapeutic safety and efficacy for a 
variety of systemic and lymphatic diseases. 
2.2 Introduction 
 Of the advances made upon liposomal platforms for drug and gene delivery over the last half-
century, surface PEGylation remains one of the most fundamentally essential in conferring clinically-
meaningful effects.13, 14 The ability to expand circulation longevity of liposomes through a decrease in 
opsonin-mediated immune cell recognition has allowed for a relevant exploitation of the enhanced 
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permeation and retention (EPR) effect in cancer therapy.6, 16, 35, 36 However, due to strong surfactant 
forces directed upon a PEGylated liposome surface, further compounded by the relatively weak 
hydrophobic exclusion effect which supports formation of a lipid bilayer around an aqueous core, 
PEGylation at greater than roughly 6-7 mol% lipids serves to dissolve the lipid bilayer structure, 
producing lower-order micelles which possess more thermodynamically-stable hydrophobic cores for a 
surface of such net positive intrinsic curvature.17 Such limitations in density likely contribute to the rapid 
clearance of these nanoparticles compared to other advanced formulations by the immune system, and 
may contribute to an acquired immune response upon subsequent injections, in particular toward the 
comparatively diverse chemical structure of the PEG-lipid conjugation site.37, 38 Therefore, effective 
means by which to PEGylate liposomes to higher densities remain desirable in the development of 
advanced nanomedicines. 
 A series of recently-developed liposomal formulations17, 29, 31 perform in such a manner by 
means of what is known as the “supported bilayer phenomenon”. Specifically, should a liposome 
possess not an aqueous core, but a solid, stable, and chemically interactive core material, the lipid 
bilayer will remain intact even under the forces conferred by increasing PEGylation density, allowing a 
progression toward the steric limits of PEGylation for each respective formulation in defiance of intrinsic 
lipid curvature.17 Considerable benefit has been wrought from these supported bilayer-based 
formulation methods in particular, including a selective and ApoE-dependent tropism of LCP for the 
hepatocytes of the liver at such high PEGylation,30 as well as notable siRNA-mediated LCP-based gene 
silencing and cisplatin-mediated LPC-based chemotherapy in the systemic treatment of various 
cancers.28, 31, 39 However, despite high PEG density, previously published work often describes marginal 
circulation longevity for LCP, in particular as the macromolecular complexity of the encapsulated 
cargoes increases.26 Further, though cells possess reliable intrinsic means by which to overcome the 
high-calcium conditions elicited through LCP-mediated endosome escape,40 cationic lipid-mediated 
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toxicity remains a concern in many nanoparticle formulation strategies.6, 41 LCP also has been shown 
capable to facilitate endosomal release even in the absence of cationic lipids through a number of 
coordinated mechanisms.30, 42, 43 Lastly, such limitations in nanoparticle performance can be traced back 
to challenges in formulation, wherein resuspension in aqueous conditions from a thin lipid film requires 
strong physical methods of agitation (vortexing, sonication) which are notoriously difficult to scale. 
Therefore, a formulation which can effectively evade immune cell recognition while supporting 
pharmaceutic and therapeutic performance in vitro would be expected to translate effectively for local 
and systemic delivery in vivo. 
 In this work, we present for the first time a liposome coated exclusively by PEGylated 
phospholipids, utilizing lipid-coated calcium phosphate (CaP) and cisplatin (Pt) cores of diverse sizes (10-
40nm) as well as varying PEG chain lengths (350-5000 Da). Fully-PEGylated LCP liposomes (PCP) show a 
chain length-dependent reduction of protein adsorption which couples with grafted PEG chain length to 
support evasion of uptake by peripheral blood mononuclear cells (PBMC), while remaining amenable to 
active targeting strategies which facilitate improved degrees of nanoparticle uptake and meaningful 
endosome escape. Further, such exclusively PEG2000-modified nanoparticles represent an outer leaflet 
lipid surface density commensurate with the formation of a lipid bilayer as well as a PEGylation density 
which interfaces at a “dense brush” conformation, avoid use of scale-limited physical resuspension 
methods, and mediate comparable therapeutic activity in vitro to advanced nanoparticle formulations. 
We expect such improved delivery properties to translate into improved therapeutic safety and efficacy 






2.3 Materials and Methods: 
2.3.1: Materials 
 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[succinyl(polyethylene glycol)-2000] 
(DSPE-PEG2000-NHS) was purchased from NOF corporation (Tokyo, Japan). DSPE-PEG2000-anisamide (AA) 
was synthesized following previously described protocols26, 27, 44 and analyzed via NMR using a Varian 
Inova 400 MHz NMR spectrometer (Palo Alto, CA). DSPE-polycarboxybetaine7K, DSPE-polysarcosine2K and 
DSPE-polysarcosine5.5K, and DSPE-poly(ethyl oxazoline) were provided as generous gifts. All other lipids, 
including fluorescently-labeled lipids, were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). 
Ultracentrifuge tubes were purchased from Beckman Coulter (Indianapolis, IN). 177Lu was purchased 
from Perkin-Elmer (Waltham, MA). All other reagents, including fluorescently-labeled oligonucleotides, 
were purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. Bench-top 
photographs were taken with an iPhone SE camera. 
2.3.2: Cell Lines 
 Three different cell lines were used in the experiments described below: NCI-H460 (H460) 
human non-small cell lung cancer cells, A375 human melanoma cells, and JAWS-II mouse monocytes 
(direct progenitor of dendritic cells). Peripheral blood mononuclear cells (PBMC) were derived fresh 
from mice via cardiac puncture and incubated in EDTA-coated tubes for experimental use. 
2.3.3: Experimental Animals 
 Six- to eight-week-old BALB/c female mice were purchased from Charles River Laboratories 
(Wilmington, MA). All work performed on animals was in accordance with and approved by the 




2.3.4: Fully-PEGylated Liposome Fabrication and Characterization 
 CaP cores were prepared using a modified protocol.30, 34 Briefly, two 5 mL 3:7 Igepal-co-520 / 
Cyclohexane w/o microemulsions were prepared – one with 150 µL dibasic ammonium phosphate (50 
mM), the other with 150 µL calcium chloride (2.5 M) (with or without soluble therapeutic). Emulsions 
were stirred for 10 min, mixed together, and stirred for an additional 10 min, followed by addition of 
62.5 µL DOPA (35 mM). After an additional 30 min of stirring, the mixture was washed repeatedly with 
absolute ethanol under centrifugation (10,000 g) to yield a precipitate purified from the excess 
surfactants. The precipitate was then resuspended in chloroform and centrifuged once more (10,000 g) 
to purify the DOPA-coated CaP cores (supernatant) from more poorly-formed nanoprecipitates (pellet). 
Encapsulation was characterized radiometrically using a gamma counter (the Nucleus, Oak Ridge, TN) or 
through a fluorescence method. 
 DOPA-coated CDDP (Pt) cores were prepared in the same fashion as CaP, but with the following 
modifications to the protocol. Oil phases were prepared as a 3:1 ratio of the following components: 3:7 
Igepal-co-520 / Cyclohexane, and 15:2:3 Cyclohexane / Hexanol / Triton X-100. 150 µL calcium chloride 
was replaced with 62.5 µL Pt(NH2)2(H2O)2 at 200 mM, and 150 µL ammonium phosphate dibasic was 
replaced with 62.5 µL KCl at 800 mM. DOPA was added to the Pt(NH2)2(H2O)2 microemulsion 
immediately after dissolution of Pt(NH2)2(H2O)2, instead of after mixing. 
 CaP or Pt cores were then mixed with a slight (2.5-fold) excess of outer-leaflet lipids in 
chloroform, dried  under nitrogen, and resuspended at 65°C under aqueous conditions (beginning with 
absolute ethanol and titrating to < 20% with additional DI water). Molar ratios of outer-leaflet lipids for 
the traditional LCP formulation follow as 1:1:1 DOTAP:Cholesterol:DSPE-PEG. Zeta potential and particle 
size were measured using a Malvern ZetaSizer Nano Series (Westborough, MA). TEM images of both 
DOPA-coated CaP cores and fully-PEGylated LCP liposomes were acquired using a JEOL 100CX II TEM 
(JEOL, Japan), the latter of which was stained with uranyl acetate (UA) as needed. 
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2.3.5: PEG-Alternative Liposome Fabrication and Characterization 
 Preparation of larger (30-40 nm) CaP cores was performed following a similar method to that of 
smaller cores, employing instead a mixed surfactant system in the emulsion.25 Encapsulation efficiency 
was characterized radiometrically using a gamma counter (the Nucleus, Oak Ridge, TN) or through a 
fluorescence method. For final LCP preparation, the protocol was modified in terms of cholesterol 
content as needed for preparation of a transparent thin film in variation of PEG chain length. For fully-
PEGylated DSPE-PEG1000 and DSPE-PEG350, dissolution in a small amount of tetrahydrofuran prior to 
aqueous dispersion facilitated optimal particle quality as well. 
 Alternative DSPE lipid conjugates included that of polysarcosine, poly(ethyl oxazoline), and 
polycarboxybetaine, which were formulated onto CaP cores as described in section 2.3.4. 
2.3.6: Ex Vivo Protein Adsorption 
 LCP nanoparticles of varying PEG chain lengths were incubated with serum and saline for 2 
hours at 37°C, and purified via aqueous and organic washes for BCA analysis. Results were background-
subtracted from solvent, and normalized to absorbance generated from the DSPE-PEG2000-coated LCP 
particles (PEG2000). 
2.3.7: Ex Vivo PBMC Uptake 
 LCP encapsulating FAM-labeled oligonucleotides and of a variable PEG density were incubated 
ex vivo in whole BALB/c mouse blood (in EDTA-coated tubes) for 2 hours, after which white blood cells 
were isolated through washes in ACK buffer and PBS until devoid of red color, and analyzed via flow 






2.3.8: Density Gradient Nanoparticle Purification 
 For surface composition analysis, LCP purification was performed via sucrose density gradient 
centrifugation. Briefly, in a centrifuge tube, layers of varying sucrose concentration (40%, 20%, 10%, and 
0%) were prepared, with nanoparticle solution comprising the top layer. Nanoparticles were labeled at 
the level of the core (177Lu) and either the inner leaflet (0.3% NBD-OPA) or the outer leaflet (1% NBD-
OPC or 1% DSPE-PEG-FITC). Samples were centrifuged using a swinging bucket rotor (60,000 rpm, 4 h, 
4°C), and visible fluorescent signal under UV illumination which penetrated into the lower sucrose layers 
was recovered. Such fractions were analyzed fluorometrically to determine the percentage of input 
fluorescence recovered (either through the CaP core preparation for NBD-OPA, or the density gradient 
centrifugation for the NBD-OPC or DSPE-PEG-FITC), and normalized radiometrically to core content, 
yielding the output in Table 2.2. 
2.3.9: Lipid Surface Density Calculation 
 The mass of recovered CaP cores was determined after drying overnight under vacuum, and the 
number of nanoparticles was estimated by a fractional core density, assuming a 12-nm average 
spherical calcium phosphate particle diameter (by TEM) and a 2.5-nm lipid monolayer of oleic acid at the 
surface. Core DOPA recovery was determined fluorometrically as the ratio of input and output NBD 
fluorescence in the CaP core formulation process. PA head group CSA was determined as the ratio of the 
total surface area of the 12-nm diameter calcium phosphate spherical precipitates formed and the 
number of DOPA recovered per batch. PC and PE head group cross-sectional areas were determined 
after sucrose density gradient centrifugation fluorometrically as a ratio between the fluorescences of 
NBD and NBD, or NBD and FITC, respectively, normalizing to recovered core content (177Lu). PEG chains 
per square nanometer at the lipid bilayer equals to the inverse of PE head group CSA. PEG chains per 
square nanometer at the PEG corona, a theoretical estimation, assumes radial increases in aspect ratio 
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as one extends 5-10 nanometers from the lipid bilayer surface, presuming a brush conformation for the 
PEG chains. 
2.3.10: Cell Uptake of Liposomes and Characterization 
 A variety of novel cell lines for our lab were explored for their overall expression levels of sigma 
receptor, including bladder cancer (UMUC3), unmodified breast cancer (4T1), and engineered breast 
cancer (4T1 GFP/Luc), using the traditional H460 lung cancer line as a positive control. Relative receptor 
expression levels were characterized through a standard Western Blot protocol. For synthesis of 
aminoethyl anisamide, a ligand for sigma receptor, in brief, amide coupling between bromoethylamine 
and methoxybenzoyl chloride was performed, followed by SN2 displacement of the conjugate bromide 
by DSPE-PEG-amine, three precipitations in ether at -80C and lyophilization.44 
 For cell uptake quantification, NBD-labeled OPA-containing LCP or PCP nanoparticles, each 
targeted with either 20% anisamide (AA) or 20% mannose (MAN) ligand, were incubated with 
(respectively) sigma receptor-expressing H460 lung cancer cells and mannose receptor-expressing 
JAWSII dendritic cells for 4 hours in Opti-MEM at 37°C and 5% CO2, after which cells were washed with 
PBS, trypsinized, washed, and characterized for fluorescence intensity by flow cytometry using a BD 
FACSCanto system. 
 For fluorescence distribution characterization, H460 cells were pulsed with PCP particles, which 
incorporated both NBD-OPA (green) and Cy5-siRNA (red) within the structure, for 3 hours at 4°C in 
RPMI-1640 which included 10% FBS. Media was then replaced and the cells cultured for an additional 3 
hours at 37°C, after which cells were washed and imaged as live cells using a Zeiss 880 series confocal 





2.3.11: Gene Silencing by CaP-Based Liposomes 
 LCP and PCP nanoparticles, each targeted with anisamide (AA) were incubated for 6 hours with 
H460 cells in reduced serum medium, after which cells were washed with PBS and imaged via 
fluorescence microscopy for delivery of Texas Red-labeled oligonucleotide. Similar efforts in delivering 
siVEGF (400 nM) were characterized for relative mRNA expression by RT-PCR according to established 
protocols. 
2.3.12: Cytotoxicity of CDDP-Liposomes 
 LCP or PCP nanoparticles, each targeted with anisamide (AA), were incubated for 6 hours with 
H460 or A375 cells in RPMI-1640 containing 10% FBS, after which media was exchanged and cells were 
allowed to proliferate an additional 54 hours. At hour 60, cell proliferation was evaluated by an MTT 
assay. 
2.3.13: Statistical Analysis 
 Data are presented as Mean ± SD. Statistical significance was defined by P < 0.05 through a two-
tailed t-test when comparing two groups, and the Holm-Sidak test for multiple comparisons. 
2.4: Results: 
2.4.1: The Supported Bilayer Phenomenon Can Facilitate Full PEGylation on the Outer Leaflet 
 Lipid-coated calcium phosphate nanoparticle (CaP) cores have proven to be an effective 
formulation mechanism for drug encapsulation and delivery, in particular for a variety of nucleic acid 
and phosphorylated peptide and pro-drug therapies which are limited in formulation within traditional 
liposomes.25-27 Previous methods for generating an outer lipid layer on such CaP cores employed a mixed 
lipid system comprising traditional bilayer-forming lipids such as DOPC and DOTAP, helper lipids such as 
cholesterol, and the antifouling polymer-lipid conjugate DSPE-PEG2000; within such a thermodynamic 
system, PEG density on the nanoparticle surface has been shown to plateau at roughly 20 mol% of total 
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outer lipid, in far excess of that which is possible through traditional liposome formulation methods 
which rely upon a planar lipid curvature for stability.30 However, CaP core coating exclusively with 
PEGylated phospholipids has yet to be explored. Herein, we present such liposomes for the first time, 
coating nanoparticle cores ranging from 10-15 nm in diameter (Figure 2.1A) exclusively with DSPE-
PEG2000 to produce a well-dispersed population around 30 nm (Figures 2.1A-B). Such particles represent 
only minor degrees of aggregation, as observed instead through a volume-averaged distribution (Figure 
2.1A) as well as a visually transparent final product compared to traditional 20 mol%-PEGylated LCP 
(Figure 2.1C). Most notable for this fully-PEGylated formulation is the ease with which one can 
resuspend such nanoparticles from a transparent thin film containing DSPE-PEG2000 through simple 
addition of fresh, absolute ethanol followed by rapid dilution with DI water in a simple process of 
solution coating and mixing, unlike the traditional 20 mol%-PEGylated LCP formulation which is 
dependent upon physical methods (i.e. vortexing, sonication) possessing meaningful industrial scale 
limitations. Given that the order of addition of the ethanol suspension and the excess water holds no 
effect on formulation quality, these findings have significant implications regarding the potential for 
industrial scalability of the fully-PEGylated LCP nanoparticle platform as well, as such conditions of 
spontaneous self-assembly lend themselves strongly to a well-known and reliably scalable process 
known as ethanol injection.45 
 Such exclusive phospho-lipopolymer coatings can be formed with a variety of PEGylation chain 
lengths and CaP core sizes as well (Figure 2.2) though the inclusion of cholesterol in the formulation, due 
predominantly to complications in homogenous and relatively transparent thin film production (in the 
case of PEG chain length, dissolution in a negligible amount of THF prior to rapid rehydration was 
advantageous in dispersing uniform nanoparticle populations. These core size-variable results have been 
recapitulated in thin film rehydration with the Pt core formulation as well, exploiting cholesterol 
39 
 
inclusion in rehydration to effectively disperse larger cores as compared with smaller Pt cores which can 
be functionalized with DSPE-PEG alone (Figure 2.3). 
2.4.2: Physicochemical Characteristics Drive PEGylation over Alternative Phospholipopolymers 
 Despite such a diversity of PEG chain lengths and nanoparticle core sizes which can be 
functionalized exclusively with PEGylated phospholipids, when progressing to alternative stealth 
polymer-lipid conjugates, such as polycarboxybetaine, polysarcosine, and poly(ethyl oxazoline), an 
inability to achieve effective dissolution of such materials with the nanoparticle core in thin film 
preparation prevented effective dispersion of such nanoparticles in all cases but that of the 
polycarboxybetaine-modified nanoparticles (Figure 2.4), whether explored as a pure thin film coating or 
as a transient dissolution in THF. Progression within this chapter will focus entirely on the PEG-lipid 
conjugates, as later chapters will reveal a lack of formulation or function for any of these alternative 
polymer-lipid conjugate systems. 
2.4.3: Surface Charge Shielding Derives from PEG Chain Length 
 Nanoparticle stealth properties derive from their ability to evade immune recognition and 
clearance within the body. Whether in facilitating protein adsorption or direct immune cell uptake 
through charge-charge interactions, nanoparticle surface potential remains as one fundamental 
characterization tool through which to determine the stealth-contributing properties of different PEG 
chain lengths, as phospholipid charge shielding serves as a contributing benefit to the steric exclusion of 
protein adsorption through modification with PEG. Therefore, laser Doppler electrophoresis (LDE) was 
employed to explore the charge shielding properties of varying PEG chain lengths of DSPE-PEG. As PEG 
chain length increased, a dramatic decrease in surface potential was observed in progressing from 




 Though charge shielding properties extended with PEG chain length, even at 5000 molecular 
weight PEG, surface potential measurements were not completely abrogated. Therefore, modification of 
fully-PEGylated LCP (PCP) with an ionizable, non-bilayer-forming lipid DC-Chol, which possesses a 
relatively neutral pKa (7.8),46 was effective at neutralizing nanoparticle surface potential when 
formulated in PCP at a 1:1 PEG:DC-Chol ratio (Figure 2.5).  
2.4.4: Ex Vivo Protein Adsorption Extends as a Function of Charge Shielding 
 Along with inefficient steric exclusion, highly charged nanoparticle surfaces can stimulate 
protein adsorption.6 Therefore, we explored the potential for protein adsorption of nanoparticles which 
showed significantly different surface potentials, despite exclusive formulation with PEGylated 
phospholipids. BCA analysis (Figure 2.6) showed that, relative to the absorbance generated by the 
PEG2000 formulation, PEG1000 produced almost two-fold greater protein adsorption, and PEG350 generated 
roughly an eight-fold difference. Therefore, as surface potential increases, despite the presence of a 
high density of PEG on each nanoparticle surface regardless of chain length, the degree of protein 
adsorption appears to follow suit. 
2.4.5: Ex Vivo PBMC Uptake Extends as a Function of Charge Shielding 
 In concert with charge shielding and in relation to protein adsorption, uptake by professional 
phagocytic populations within the body serves as a primary clearance mechanism for nanoparticles. 
While resident macrophages within the liver and spleen serve as the primary depot for such 
nanoparticle clearance,6 a relevant exploration of a supposedly “stealth” formulation should include 
characterization of the intrinsic nature of these nanoparticles in relation to circulating white blood cell 
populations (specifically, peripheral blood mononuclear cells, or PBMC, which include monocytes, 
leukocytes, and macrophages). Therefore, we incubated LCP of different PEG density within whole blood 
samples to characterize whether the well-performing PEG2000-modified PCP nanoparticles effectively 
41 
 
evade uptake within circulating monocytes. In contrast to a highly cationic nanoparticle (Figure 2.7), 
which is taken up to such high degrees that the gated population experiences a dramatic shift in 
scattering (data not shown), the PEG2000-PCP exhibits a lack of meaningful monocytes uptake at in vivo 
nanoparticle dosing levels. 
2.4.6: Density Gradient Nanoparticle Purification Facilitates Nanoparticle Surface Characterization 
 As the PEG2000-PCP formulation has exhibited an effective charge shielding and steric exclusion 
to protein adsorption sufficient to evade uptake by PBMCs, it would be of great interest to consider the 
specific density of PEGylation such a nanoparticle surface achieves, particularly due to its ease of 
formulation and stability in complex aqueous solutions. However, to consider accurately the density of 
lipid coverage on the surface of CaP cores, purification of such cores from the free PEG-lipid micelles 
intrinsic to the thin-film preparation and hydration process remains necessary. To perform this 
purification, we can exploit the density differences between PCP and PEG-lipid micelles through density 
gradient centrifugation through varying concentrations of aqueous sucrose, as the CaP core provides 
non-negligible increases in particle density to the overall nanoparticle. When fluorescently labeled at the 
inner leaflet, outer leaflet, or PEG corona, one can observe strong accumulation within a narrow band at 
the interface between the 20% and 40% sucrose layers (Figure 2.8). Further, the ability not only to 
harvest such layers, not only to functionalize each lipid leaflet as well as PEG, but the ability to normalize 
such fluorescent measurements to a radionuclide (177Lu) which is stably encapsulated within the 
nanoparticle core allows us incomparable ease in aliquot recovery for fluorometric measurement 
through radiometric normalization. Put more simply, with the knowledge of exactly how many 
nanoparticle cores we recover (in knowing the total core number per batch through mass measurement 
and density calculation), we can effectively normalize our fluorescence recovery to determine a 
relatively accurate lipid surface density at both inner and outer leaflets per nanoparticle. 
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2.4.7: Lipid Surface Density Conveys Equivalence to Spontaneously-Assembled Bilayers 
 Unique to CaP cores is the dense coating of DOPA on the calcium phosphate nanoparticle 
surface, which is underscored by the maintenance of such high-density particles (theoretical specific 
activity ~ 1.6) in suspension in chloroform under high separation forces (centrifugation at 10,000 g). 
Traditional bilayer-forming lipids such as DOPA (under deionized conditions) or DOPC, when assembled 
into a lipid bilayer structure, possess head group cross-sectional areas (CSA) on the sub-nm2 level.47 
Further, a head group CSA in great excess of that of the acyl chains will drive micellar formulation in 
aqueous suspension, as in the case of DSPE-PEG alone, preventing the full PEGylation of a traditional 
liposome possessing an aqueous core. Given the stability of our CaP cores in suspension under high 
separation forces, and our ability to formulate CaP cores exclusively on the outer leaflet with DSPE-PEG, 
we desired to characterize the lipid packing density on the surface of the calcium phosphate 
precipitates, in terms of proposed inner leaflet and outer leaflet. Given the obvious thermodynamic 
discrepancies between traditional liposomes and LCP, as well as the significant reduction in size of our 
formulations with regard to the capabilities of traditional liposomes, our goals herein were limited to 
ascertaining whether DOPA within the inner leaflet and/or DSPE-PEG2000 on the outer leaflet organizes 
on the surface of the calcium phosphate cores in a density commensurate with traditional bilayer-
forming lipids. To characterize these nanoparticles at each level of the formulation, we expanded upon 
an established protocol of density-gradient centrifugation,30 utilizing the following components for 
quantitation: 177Lu, a radionuclide whose solubility product equilibrium favors encapsulation within the 
calcium phosphate precipitate of the CaP core; NBD-OPA, a fluorescent lipid used in small proportions to 
ascertain the DOPA content within the bulk CaP core; NBD-OPC, a fluorescent analogue of DOPC which 
functions similarly for outer leaflet quantitation; and DSPE-PEG2000-FITC. Thus, at each level of the 
particle (core, inner leaflet, outer leaflet, PEG corona), we possess a means by which to characterize the 
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particles after purification under sucrose density gradient, wherein the nanoparticles accumulate as a 
narrow band (Figure 2.8) and can be harvested and analyzed both radiometrically and fluorometrically. 
 Table 1 summarizes these measurements based on the fractional densities of both calcium 
phosphate and oleic acid within the 12-nm CaP cores (Figure 1B). Therein, we observe PA, PC, and PE 
head group CSA on the sub-nm2 level, which suggests a density of lipid packing commensurate with 
traditional bilayer formation for both traditional LCP as well as its fully-PEGylated counterpart, despite 
working with a nanoparticle for which the aqueous core analogue (a liposome appx. 20 nm in diameter) 
would be entirely unstable. These data represent the first determination of liposome packing density for 
the LCP system as well. Further, considerations of PEG chain length and packing density from previous 
work on covalently-linked polymeric beads (Figure 1.3, which will be of great interest in the context of 
circulation longevity moving forward in the next chapter) relates strongly to the ex vivo phenomena we 
observe herein. Both the strong degree of protein adsorption of PEG350-PCP and the uptake of LCP of 
minor (1 mol%) PEGylation density conforms to the expectation that only upon reaching a dense brush 
conformation can a truly immune-evasive nanoparticle be formulated. 
2.4.8: Full PEGylation Improves Cellular Internalization over Traditional LCP 
 Before moving forward with nanoparticle pharmaceutics properties, it is helpful to briefly 
outline the formulation strategies for an actively-targeted liposomal nanoparticle herein. DSPE-PEG 
facilitates a considerable potential for modification with small-molecule ligands in formulation, and over 
the years our lab has developed strong capabilities in chemical synthesis therein.44 As an example, 
aminoethyl anisamide (AA) is a known ligand for sigma receptors which are overexpressed on a variety 
of cancer cells. Figure 2.9 outlines a Western blot which explores a variety of novel cell lines to our lab 
for sigma receptor expression, in particular discovering an engineered 4T1 cell line which will be of novel 
interest in later chapters in developing an orthotopic syngeneic mouse model. Further, Figure 2.10 
outlines the synthetic product DSPE-PEG-AA in its structure as well as its characteristic NMR spectrum, 
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through which purity can be assessed ratiometrically between the integrations of the methyl carbon 
hydrogens (triplet near 1 ppm) at the acyl chain ends of DSPE and the benzyl hydrogens (doublet of 
doublets at 6.9 and 8.1 ppm) of AA, both unique structural species to the molecule. To benchmark 
ligand performance, PCP encapsulating radionuclide 177Lu was modified with DSPE-PEG-AA (PCP-AA) for 
uptake into 4T1 cells, which were subsequently washed, trypsinized, and pelleted for radiometric 
quantification, showing a marked increase in nanoparticle uptake (Figure 2.10, top right). Thus, we can 
observe an effectively-incorporated targeting system for nanoparticle delivery. 
 Given an exclusively PEGylated system of relatively high PEG density, effective charge-shielding 
and steric-exclusion properties, and a proven capability in evading immune cell uptake, a concern for the 
formulation moving forward as an in vivo drug delivery system would be its performance in exactly that 
capacity. As a comparison to other advanced lipid-based formulations, without an inclusion of cationic 
bilayer-forming lipids in the formulation, it would be relevant to determine if an exclusively-PEGylated 
liposome be able to function to a comparable degree without further intervention. Therefore, both PCP 
and LCP (the latter being 20 mol%-functionalized with PEG2000) labeled by NBD-OPA were targeted either 
through aminoethyl anisamide (AA) or mannopyranoside (MAN) ligands to, respectively, sigma receptor-
expressing H460 cells or mannose receptor-expressing JAWS-II cells for uptake in vitro. Analysis of the 
total degree of cell uptake via flow cytometry revealed an improved internalization for PCP compared to 
LCP in both cases (Figure 2.11), quantifiable as a 7-fold and 3-fold increase in respective cell lines. 
Therefore, PCP represents an improved formulation compared with LCP for nanoparticle internalization 
by a variety of cell lines. 
 Further, the degree to which such nanoparticles can generate meaningful drug release in the 
absence of cationic lipid would be of great interest as well, although previous in vivo data suggests this 
to be a strong possibility through osmotic bursting capabilities supported by the acid-sensitive CaP core 
alone.30 Therefore, dual-labeled nanoparticles were utilized in a pulse-chase uptake experiment in vitro, 
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wherein nanoparticle tracking through NBD-OPA could be differentiated from a Cy5-labeled 
oligonucleotide. Confocal z-stack (Figure 2.12) shows clear separation of the fluorescent lipid, now 
incorporated within the endo-lysosomal trafficking pathway, from the therapeutic cargo over multiple 
microns of distance, conveying an effective drug release from the nanoparticle after internalization into 
cells in vitro. 
2.4.9: Full PEGylation Elicits Comparable Therapeutic Effect to Traditional LCP 
 After clarifying drug uptake and release capabilities of the novel PCP formulation, quantitative 
comparison of drug performance to the traditional 20 mol%-PEGylated LCP formulation was seen as an 
obvious extension. Therefore, both gene silencing and cytotoxic chemotherapy were explored as 
mechanistic bases for PCP performance characterization in vitro. RT-PCR (Figure 2.13) represents 
effective gene silencing from both formulations at equivalent doses of siRNA against vascular 
endothelial growth factor (siVEGF), which corresponds to the comparable degrees of fluorescence 
derived after uptake of nanoparticles containing Texas Red-labeled oligonucleotides. However, the most 
direct quantitation of comparative nanoparticle performance was derived instead through the LPC 
nanoparticle platform, wherein concentration-dependent in vitro proliferation (Figure 2.14 and Table 
2.3) reveals PPC to be nearly equivalent to LPC as a cytotoxic agent in vitro, maintaining the orders-of-
magnitude increases in performance as compared with free cisplatin (CDDP). 
2.5: Discussion 
 Previous work has suggested, through variable lipid input ratios in a mixed-lipid system and 
surface ratio quantification after density gradient separation from free lipid, that the maximum 
PEGylation density on the CaP core platform is 20 mol%.30 Such an explanation, given the local 
experimental data and steric logic, is at face value reasonable. However, we have shown herein the 
ability to PEGylate such nanoparticle surfaces exclusively in a chain length-, core type-, and core size-
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independent fashion, albeit with inclusion of non-bilayer-forming cholesterol as a dispersal agent when 
necessary. Such astonishing findings, particularly given the sources of both sets of results, underscore 
the peculiar nature of thin film hydration in the absence of traditional bilayer-forming lipids. First, the 
addition of fresh, absolute ethanol to the thin film was found to greatly enhance the reproducibility of 
the formulation; it is likely that the PEG-lipid dominates the hydration process absent any confounding 
materials and stabilizes the formulation prior to its dilution and global stabilization in excess water. 
Further, traditional bilayer-forming lipids, even at extraordinarily small proportions within the 
formulation (5 mol%), served to disrupt the formulation such that only large aggregates were observed 
(e.g. histogram peaks via DLS; data not shown). It is therefore a unique characteristic of exclusive 
PEGylation, at least in the scope through which we have tested, that such particles can be formed at all. 
Moreover, the lack of sonication inherent to the ability to form such particles is likely a function of the 
observed increased wettability of the thin film by absolute ethanol in comparison to pure water – 
resuspension happens on much faster time scales and likely facilitates a greater dispersion of the 
formulation during the process, which would be beneficial considering the heterogeneous 
conformational association of PEG-lipid and core which would occur in a thin film. Such a lack of 
sonication necessity for reproducible nanoparticle resuspension also supports the path to translation of 
these particles in terms of industrial scalability, as an ethanol injection process design, which comprises 
simple suspension mixing rather than high-energy physical methods of dispersion, is known to be a far-
preferred formulation method. Lastly, the inclusion of cholesterol appears to act as a dispersing agent 
from the thin film, similar to the utilization of carbohydrates in rehydration from lyophilization, as well 
as a non-negligible contributor to nanoparticle surface area which facilitates the extension of full 
PEGylation to larger CaP and Pt core sizes. 
 Put together, these phenomena all suggest a dense PEG coating at the nanoparticle surface and, 
more importantly, motivate the exploration of surface density performed herein, which represented 
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equivalent lipid packing densities to traditional LCP as well as to traditional lipid bilayers. Such results 
may at first glance seem surprising for a bilayer system which exclusively incorporates DSPE-PEG on the 
outer leaflet, as they both contradict previous findings which argue for a steric limit of 20 mol% PEG on 
LCP and suggest a relatively high density of PEG (appx. one PEG chains per nm2) for a spontaneously 
organized surface. It is helpful to begin by considering the differences in the thermodynamics and kinetic 
processes at play between a mixed-lipid system and one wherein DSPE-PEG is the only bilayer-forming 
lipid. Upon initial resuspension and steric stabilization of the CaP cores in a mixed-lipid system, the 
formation of the outer leaflet at final density can be viewed as a competitive insertion process between 
the two (or more) bilayer-forming lipids involved. As the substantially small polar headgroup of DOPC in 
relation to DSPE-PEG is self-evident, one can easily expect its insertion process to be at a strong 
competitive advantage, independent of the input lipid ratio in film rehydration. This comprises the 
argument made from previous work, which shows a plateau of PEG density at 20 mol% outer leaflet lipid 
on the LCP nanoparticle despite higher input proportions. However, in a single-component system, 
there is simply no other kinetic process in competition with DSPE-PEG insertion; thus, while we would 
expect that (if such a process were readily measurable) DSPE-PEG insertion would happen over longer 
time scales than that of DOPC, such kinetic differences do not in and of themselves preclude full 
PEGylation of the CaP nanoparticle core. 
 Nevertheless, the specifically high density which we observe for the fully-PEGylated system 
requires explanation, and in this case, the high aspect ratio of such nanoparticle cores (~10 nm) must be 
emphasized in this formulation in comparison to traditional liposomal formulations such as Doxil (~100 
nm) must not be ignored. As the PEG corona occupies a majority of the total volume of the fully-
PEGylated LCP, one can clearly envision the multiple-fold increases in free volume as one expands 
outward radially, along with the underlying entropic benefits (Figure 2.15). Thus, at the distal ends of 
the PEG corona on these PEGylated LCP nanoparticles (a 5-10 nm radial expansion as observed by DLS, 
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and a relatively conservative benchmark for a brush-conforming PEGylation density), one can easily 
consider a far less densely-packed polymer system, particularly where entropic benefit is most easily 
accessible for the polymer chains. Moreover, this expansion of free volume is most evident when 
considering the larger CaP cores (Figure 2.3), which cannot be resuspended effectively without the 
presence of a lesser proportion of cholesterol (2:1 PEG:Chol). Larger cores of 30-40 nm CaP diameter 
possess far less an increase in aspect ratio as one expands outward radially; thus cholesterol, which 
possesses non-negligible surface area occupancy in its own right within the bilayer, as well as a negative 
intrinsic curvature in colloidal suspension, serves to expand the initial free volume occupied by the PEG 
chains and support colloidal stability and entropic gains at the level of the lipid bilayer rather than at the 
PEG corona. Further studies to thoroughly characterize the lipid character on such nanoparticles remain 
necessary; however, a bilayer organization of lipids represents the most reasonable interpretation of the 
LCP nanoparticle surface. 
 Given such strong formulation capabilities and flexibility with PEG, we were excited at the 
opportunity to explore such efforts with alternative phospholipopolymers, particularly those based on 
polymers synthesized in a highly controlled fashion. Whether carboxybetaines through atom-transfer 
radical polymerization (ATRP) or sarcosines and ethyl oxazolines through cationic ring-opening 
polymerization (ROP), the potential to control polymer polydispersity through “living” reaction methods 
(Figure 2.4), which minimize the reactive potential of chain termination by coupling, has opened up 
opportunities for a variety of materials which possess stealth properties in particle functionalization. 
Though the relative insolubility of such materials in solvents compatible with CaP or Pt nanoparticle 
cores prevented effective functionalization of such particles in formulation, excitement remains for 
novel materials in that the supported bilayer platform provides a mechanism not only to PEGylate the 
outer leaflet exclusively, but to do so utilizing macromolecular materials which would self-organize into 
micelles under any alternative conditions of spontaneous self-assembly. In essence, the formulation 
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process herein describes not a traditional bilayer assembly, but rather a bilayer-like organization of 
micellar lipid conjugates around a pre-formed, monolayer-bearing core – again emphasizing the 
importance of the packing density calculations conducted herein. Thus, our PCP platform can be 
confirmed to support an outer leaflet independent of phyisco-chemical considerations which drive 
traditional liposome and polymersome formation. 
 However, the expansive potential of PEGylation has allowed for exploration of a variety of 
physical and chemical phenomena considered previously on covalently conjugated polymeric surfaces, 
but not on a spontaneously self-assembled lipid bilayer at such high PEGylation densities. In these 
capacities, the relationship between nanoparticle surface charge and protein adsorption as well as 
mononuclear phagocyte uptake holds consistent, with the PEG2000-PCP particles performing with 
particular efficacy as a potential stealth formulation. This was of great interest in exploration due to 
recent work which suggests that exceedingly small PEG chain lengths (in their case, 559 Da) were still 
capable of eliciting immune-evasive properties; however, the DSPE-PEG350 conjugates which we tested 
were extraordinarily unstable under saline conditions, even in the absence of serum protein, and such 
instability likely accounts for much of the dramatic increase in protein adsorption on such fully-
PEGylated particles. 
  Further, the improved internalization, robust endosome escape, and efficacy in both gene 
silencing and cytotoxic chemotherapy suggest strong potential for in vivo study (explored in the next 
two chapters), most notably in the case of the latter, whose strong outperformance of free drug belies 
the strength of the bystander effect characteristic of the Pt core platform, which we will discuss in 
greater detail in the next chapter.31 As we move forward, we will begin to extend such fully-PEGylated 
liposomes’ improved formulation properties, grounded in diverse physicochemical particle 
characterization, toward an enhanced systemic stealth and local lymphatic drainage, both of which can 
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be paired effectively to yield enhanced therapeutic performance in respective conditions of cancer 
chemotherapy and immune stimulation. 
2.6: Conclusions 
 Despite previous findings which suggested otherwise, CaP and Pt cores of diverse sizes (10-40 
nm) can be functionalized exclusively with PEGylated phospholipids of diverse PEG chain lengths (350-
5000 Da) through spontaneous self-assembly in rehydrating a thin film. Such particles exhibit PEG chain 
length-dependent surface charge shielding and protein adsorption, contributing at high PEGylation 
densities to effective evasion of PEG2000-PCP by PBMCs ex vivo. Such particles exhibit lipid packing 
densities commensurate to both the traditional LCP formulation incorporating 20 mol% PEG, as well as 
that of a traditional lipid bilayer surrounding an aqueous core. Further, such particles exhibit an 
improved internalization into a variety of cell lines, a robust means of endosome escape, and perform 
comparably to the traditional LCP formulation in both gene silencing and cytotoxic chemotherapy 
potential in vitro. In later chapters, we will explore the characteristics of these particles in vivo through 
systemic delivery to the liver and solid tumors for chemotherapy as well as through local delivery for 














Figure 2.1: LCP Coated Exclusively by PEGylated Phospholipids. LCP cores were rehydrated from a 
clear, transparent thin film under high ethanol conditions, with optimal resuspension occurring with 
fresh absolute ethanol at 65°C, followed by rapid dilution with deionized water. TEM images (B) and 
DLS measurements (A) convey a well-dispersed and highly transparent CaP core population in 













Figure 2.2: LCP Coated Exclusively by Alternative PEGylated Phospholipids. Cores of varying CaP 
precipitate diameters were resuspended effectively with a variety of lipid-polymer conjugates serving 
as the sole phospholipid in the formulation. (A) DSPE-PEG conjugates of varying PEG chain length can 
be employed to produce uniform dispersions of CaP precipitates. (B) CaP precipitates of larger core 
size are amenable to modification with DSPE-PEG2000, although requiring moderate cholesterol (2:1 














Figure 2.3: LPC Coated Exclusively by PEGylated Phospholipids. LPC cores of varying CDDP precipitate 
diameters were resuspended effectively with DSPE-PEG2000 conjugates. (A) DSPE-PEG conjugates in 
the presence of lesser amounts of cholesterol can be employed to produce uniform dispersions of 
CDDP precipitates. (B) CDDP precipitates of smaller core size can employ DSPE-PEG2000 exclusively to 
















Figure 2.4: Attempts to Coat LCP Exclusively by Alternative Phospho-lipopolymers. A variety of novel 

















Figure 2.5: PCP is Compatible with Ionizable Non-Bilayer-Forming Lipids. CaP cores were resuspended 
effectively with DSPE-PEG2000 conjugates and DC-Chol (1:1) and characterized by dynamic light 






















Table 2.1: Characterization of PCP Liposomes. Particle size was determined via dynamic light 




















Figure 2.6: Ex Vivo Protein Adsorption onto PCP of Varying Outer Leaflet PEG Chain Lengths. PCP 
nanoparticles of varying PEG chain lengths were incubated with serum and saline for 2 hours at 37°C, 
and purified via aqueous and organic washes for BCA analysis. Results were background-subtracted 





































Figure 2.7: Ex Vivo Uptake of LCP, PCP by PBMC. LCP encapsulating FAM-labeled oligonucleotides and 
of a variable PEG density were incubated ex vivo in whole BALB/c mouse blood (in EDTA-coated 
tubes) for 2 hours, after which leukocytes were isolated through washes in ACK buffer and PBS until 
devoid of red blood cells, and analyzed via flow cytometry, gating for peripheral blood mononuclear 
cells (PBMC; monocytes, leukocytes, and macrophages). **Quantitation for LCP likely underestimates 









Figure 2.8: LCP Isolated via Sucrose Density Gradient Centrifugation. LCP cores were coated with 
DSPE-PEG2000 containing trace amounts of both 177Lu and one of the following components: NBD-
OPA, NBD-OPC, or DSPE-PEG2000-FITC.  (A) Schematic of the centrifuge tube, with solutions of sucrose 
at various weight percentages established as discrete density layers. (B) Sample results with fully-
PEGylated LCP preparations containing either 0.3% NBD-OPA or 1% DSPE-PEG-FITC. The red arrow 















Table 2.2: Determination of PEG Density on LCP Liposomes. LCP nanoparticles comprising cores 
encapsulating 177Lu, coated with either 20 mol% or 100 mol% DSPE-PEG2k, and incorporating trace 
amounts of NBD-OPA, NBD-OPC, or DSPE-PEG-FITC, were purified via sucrose gradient centrifugation, 














Figure 2.9: Engineered 4T1 cells Express High Degrees of Sigma Receptor. A variety of novel cell lines 
for our lab were explored for their overall expression levels of sigma receptor, including bladder 
cancer (UMUC3), unmodified breast cancer (4T1), and engineered breast cancer (4T1 GFP/Luc), using 
the traditional H460 lung cancer line as a positive control. Relative receptor expression levels were 



















Figure 2.10: Radiometric Quantification Confirms 4T1 Targeting Enhancement via Anisamide Ligand. 
Aminoethyl anisamide was synthesized through amide coupling between bromoethylamine and 
methoxybenzoyl chloride, followed by SN2 displacement of the conjugate bromide by DSPE-PEG-
amine. NMR characterization (bottom) reveals high conjugation purity. Formulation with fully-













Figure 2.11: In Vitro Cell Uptake of LCP. NBD-labeled LCP particles consisting of either 100 mol%  (PCP) 
or 20 mol% (LCP) DSPE-PEG2k and targeted with either anisamide or mannose ligand were incubated 
with (respectively) sigma receptor-expressing H460 cells and mannose receptor-expressing JAWS-II 













Figure 2.12: Cargo release after cell uptake. H460 cells were pulsed with PCP particles, which 
incorporated both NBD-OPA (green) and Cy5-siRNA (red) within the structure, for 3 hours at 4°C in 
RPMI-1640 which included 10% FBS. Media was then replaced and the cells cultured for an additional 
3 hours at 37°C, after which cells were washed and imaged as live cells using a Zeiss 880 series 










Figure 2.13: Gene Silencing in vitro with LCP Nanoparticles. LCP and PCP, each targeted with 
anisamide (AA), were incubated for 6 hours with H460 cells in reduced serum medium, after which 
cells were washed with PBS and imaged via fluorescence microscopy for delivery of Texas Red-labeled 
oligonucleotide. Similar efforts in delivering siVEGF (400 nM) were characterized for relative mRNA 















Figure 2.14: Platinum Toxicity in vitro with LPC Nanoparticles. Cell proliferation versus free cisplatin 

















Figure 2.15: Aspect Ratio Increases Underlie the High PEG Density Observed on CaP Nanoprecipitates. 
As one expands outward radially from the nanoparticle core, to the lipid bilayer surface, to the PEG 
corona, when one is working with nanoparticles on the small size scale equivalent to polymer 
persistence length, increases in aspect ratio as one expands outward radially become profound, 
yielding near-order-of-magnitude increases in free volume available to such PEG polymers for 
conformational exploration. As the polymer is fixed at the bilayer surface, free volume expansion at 
the PEG corona is by definition more entropically valuable than at the nanoparticle surface, 












Table 2.3: Platinum Toxicity in vitro with LPC Nanoparticles. Cell proliferation versus free cisplatin was 



















Figure 2.16: 3D Representation and Structural Cartoon of Fully-PEGylated Liposomal Nanoprecipitates. 















CHAPTER 3: FULLY-PEGYLATED LIPOSOMES FOR ENHANCED SYSTEMIC DELIVERY 
3.1: Summary 
 Novel liposomes densely coated exclusively with PEGylated phospholipids (PCP, PPC) have been 
developed, through exploitation of the supported bilayer phenomenon, which exhibit effective stealth 
properties in ex vivo studies while improving cell uptake and therapeutic function in vitro in comparison 
to traditional formulations. In this work, we present the enhanced systemic delivery capabilities of such 
nanoparticles in vivo, focusing upon delivery to both liver and tumor. These PCP liposomes exhibit a PEG 
chain length-dependent circulation longevity and stealth property in biodistribution that is independent 
of nanoparticle core size, outperforming the traditional LCP nanoparticle system in abrogation of rapid 
distribution clearance upon intravenous injection. Major organ biodistribution of these PCP liposomes 
shows a chain length-dependent stealth evasion of traditional organs of nanoparticle clearance as well, 
which can be resolved completely through simple active targeting mechanisms, and facilitates dose-
normalized accumulation ratios between tumor and liver or spleen in excess of that of LCP. At the 
PEG2000 level, the highest performing of the chain lengths tested, PCP facilitates the PEG density-
dependent passive tropism to primary hepatocytes observed in previous studies, and in an ASGPR-
targeted mechanism, can support competitive degrees of transgene expression within the liver with 
minimal off-target effects absent any cationic lipid in formulation. In terms of delivery to solid tumors, 
the enhanced neighboring effect of the Pt nanoparticle core platform can be leveraged in the same 
manner to facilitate meaningful tumor growth inhibition absent cationic lipid, and in a non-toxic 
multiple-dosing regimen of platinum in contrast to that with even ionizable cationic lipid. Given these 
results, PCP represents a competitive, cation-free formulation basis for mediating therapeutic effect in 
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vivo compared with LCP while benefiting from enhanced formulation properties which support a clearer 
path to translation moving forward. 
3.2: Introduction 
 In the previous chapter, full PEGylation of a spontaneously self-assembled liposome outer 
leaflet was described for the first time, exhibiting both ex vivo stealth properties and in vitro therapeutic 
performance either comparable to or in excess of the traditional liposomal nanoprecipitate formulations 
at 20 mol% PEGylation. Such benefits included a PEG chain length-dependent reduction in protein 
adsorption, a PEG density-dependent reduction in PBMC uptake, improved active internalization into 
cancer and immune cell lines, capable endosome escape, and comparable dose-dependent therapeutic 
effect to the traditional formulations. Further, the high PEGylation density such fully-PEGylated 
nanoparticles employ was determined to hold particularly consistent lipid packing at the bilayer surface 
to that of traditional formulations which employ intrinsically bilayer-forming lipids such as DOPC. In all, 
such nanoparticles represented at the ex vivo level a competitive performance both pharmaceutically 
and therapeutically, generating strong interest in translation of such systems to in vivo conditions of 
systemic drug delivery. 
 While expecting to recapitulate previous physical variations within these nanoparticles at the in 
vivo level, of particular interest for these fully-PEGylated (or PCP) liposomes was their potential for 
performance in delivery to both primary hepatocytes as well as solid tumors. Previous studies using LCP 
have shown that increasing PEG density from 5 to 20 mol% presents a gradual shift in natural tropism 
within the liver from Kupffer cells, the resident immune scavengers of the reticuloendothelial system 
(RES), to the primary hepatocytes, facilitating expansive and diffuse gene delivery across the liver.30 
Further, a potential for increased nanoparticle stealth properties could facilitate pharmaceutics benefits 
across the delivery process, from increased circulation longevity, to strong evasion of traditional organs 
of nanoparticle clearance (liver, kidneys, spleen, lung), to ultimately a dose-normalized accumulation of 
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nanoparticle between tumor and non-tumor, which increasingly represents the benchmark for effective 
delivery through the passive process of enhanced permeation and retention (EPR) within the tumor. 
Lastly, amenable active targeting through small-molecule ligands having been shown in the previous 
chapter as well, a focused particle distribution to the liver and uptake within the tumor were expected 
to perform capably through the full PEGylation strategy as well. 
 However, given liposomes comprised on the outer leaflet exclusively of PEGylated phospholipids 
(the only bilayer-forming lipids ever included in the PCP formulation), the greatest interest lay in direct 
comparison to the traditional LCP formulation, not simply due to its limited circulation longevity as 
described previously, but in its basic functional inclusion of cationic lipids within the formulation. While 
highly-performing in their ability to influence extracellular interaction and intracellular endosome 
rupture, concerns for such lipids’ toxicity in vitro and in vivo still remain.6 In recent years, however, 
extensive research has expanded into high-throughput generation of vast libraries of not only cationic 
lipids, but so-called “ionizable lipids” possessing basic amines of pKa values within relevant endosomal 
acidification ranges (appx. pH 5-7), allowing for limited cation presentation and toxicity along the path of 
delivery while still facilitating endosome disruption upon particle internalization.48-50 Therefore, direct 
comparison not only to LCP, but PCP incorporating an ionizable lipid DC-Chol, described in the previous 
chapter, can lend meaningful and relatively direct insights into such potential formulation capabilities 
and benefits in vivo. 
 Herein, we present the enhanced systemic delivery capabilities of PCP particles in vivo, focusing 
upon delivery to both liver and tumor. These PCP liposomes exhibit a PEG chain length-dependent 
circulation longevity and stealth property in biodistribution that is independent of nanoparticle core 
size, outperforming the traditional LCP nanoparticle system in abrogation of rapid distribution clearance 
upon intravenous injection. Major organ biodistribution of these PCP liposomes shows a chain length-
dependent stealth evasion of traditional organs of nanoparticle clearance as well, which can be resolved 
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completely through simple active targeting mechanisms, and facilitates dose-normalized accumulation 
ratios between tumor and liver or spleen in excess of that of LCP. At the PEG2000 level, the highest 
performing of the chain lengths tested, PCP facilitates the PEG density-dependent passive tropism to 
primary hepatocytes observed in previous studies, and in an ASGPR-targeted mechanism, can support 
competitive degrees of transgene expression within the liver with minimal off-target effects absent any 
cationic lipid in formulation. In terms of delivery to solid tumors, the enhanced neighboring effect of the 
Pt nanoparticle core platform can be leveraged in the same manner to facilitate meaningful tumor 
growth inhibition absent cationic lipid, and in a non-toxic multiple-dosing regimen of platinum in 
contrast to that with even ionizable cationic lipid. Given these results, PCP represents a competitive, 
cation-free formulation basis for mediating therapeutic effect in vivo compared with LCP while 
benefiting from enhanced formulation properties which support a clearer path to translation moving 
forward. 
3.3 Materials and Methods: 
3.3.1: Materials 
 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[succinyl(polyethylene glycol)-2000] 
(DSPE-PEG2000-NHS) was purchased from NOF corporation (Tokyo, Japan). DSPE-PEG2000-anisamide (AA) 
and DSPE-PEG2000-galactose (GAL) were synthesized following previously described protocols
26, 27, 44 and 
analyzed via NMR using a Varian Inova 400 MHz NMR spectrometer (Palo Alto, CA). All other lipids, 
including fluorescently-labeled lipids, were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). 
Ultracentrifuge tubes were purchased from Beckman Coulter (Indianapolis, IN). 177Lu was purchased 
from Perkin-Elmer (Waltham, MA). All other reagents, including fluorescently-labeled oligonucleotides, 




3.3.2: Cell Lines 
 Three different cell lines were used in the experiments described below: NCI-H460 (H460) 
human non-small cell lung cancer cells, A375 human melanoma cells, and 4T1 mouse breast cancer cells 
(stably engineered to express GFP and firefly luciferase). 
3.3.3: Experimental Animals 
 Six- to eight-week-old BALB/c female mice were purchased from Charles River Laboratories 
(Wilmington, MA). All work performed on animals was in accordance with and approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
3.3.4: Preparation and Characterization of Fully-PEGylated LCP Nanoparticles 
 Fully-PEGylated LCPs were prepared using a modified protocol.30, 34 Briefly, two 5 mL 3:7 Igepal 
co-520:Cyclohexane w/o microemulsions were prepared – one with 150 µL dibasic ammonium 
phosphate (50 mM), the other with 150 µL calcium chloride (2.5 M) (with or without soluble 
therapeutic). Emulsions were stirred for 10 min, mixed together, and stirred for an additional 10 min, 
followed by addition of 62.5 µL DOPA (35 mM). After an additional 30 min of stirring, the mixture was 
washed repeatedly with absolute ethanol under centrifugation (10,000 g) to yield a precipitate purified 
from the excess surfactants. The precipitate was then resuspended in chloroform and centrifuged once 
more (10,000 g) to purify the DOPA-coated CaP cores (supernatant) from more poorly-formed 
nanoprecipitates (pellet). Encapsulation was characterized radiometrically using a gamma counter (the 
Nucleus, Oak Ridge, TN) or through a fluorescence method. 
 CaP cores were then mixed with an excess of outer-leaflet lipids in chloroform (about 2.5- to 5-
fold, depending on the degree of aggregation experienced in resuspension), dried under nitrogen, and 
resuspended at 65°C under aqueous conditions (beginning with absolute ethanol and titrating to < 20% 
with additional DI water). Cholesterol was added to the preparation, particularly for larger nanoparticle 
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cores, in order to improve dispersion in rehydration, and comparative studies between PCP and LCP 
involved equimolar proportions of bilayer-forming lipids (in the case of CaP nanoparticles, DOTAP and 
DSPE-PEG). 
 DOPA-coated CDDP (Pt) cores were prepared in the same fashion as CaP, but with the following 
modifications to the protocol. Oil phases were prepared as a 3:1 ratio of the following components: 3:7 
Igepal-co-520 / Cyclohexane, and 15:2:3 Cyclohexane / Hexanol / Triton X-100. 150 µL calcium chloride 
was replaced with 62.5 µL Pt(NH2)2(H2O)2 at 200 mM, and 150 µL ammonium phosphate dibasic was 
replaced with 62.5 µL KCl at 800 mM. DOPA was added to the Pt(NH2)2(H2O)2 microemulsion 
immediately after dissolution of Pt(NH2)2(H2O)2, instead of after mixing. 
3.3.5: PEG-Alternative Liposome Fabrication and Characterization 
 Preparation of larger (30-40 nm) CaP cores was performed following a similar method to that of 
smaller cores, employing instead a mixed surfactant system in the emulsion.25 Encapsulation efficiency 
was characterized radiometrically using a gamma counter (the Nucleus, Oak Ridge, TN) or through a 
fluorescence method. For final LCP preparation, the protocol was modified in terms of cholesterol 
content as needed for preparation of a transparent thin film in variation of PEG chain length. For fully-
PEGylated DSPE-PEG1000 and DSPE-PEG350, dissolution in a small amount of tetrahydrofuran prior to 
aqueous dispersion facilitated optimal particle quality as well. 
3.3.6: Pharmacokinetics and Biodistribution of Fully-PEGylated LCP Nanoparticles 
 BALB/c mice were injected intravenously (via tail vein) with nanoparticle suspensions 
(supplemented with 5% glucose to balance osmolarity). For kinetics studies, blood samples were 
extracted serially via tail clip, with the final time point obtained via cardiac puncture. For studies in 
tumor-bearing mice, orthotopic 4T1 tumors were produced in BALB/c mice through subcutaneous 
inoculation of 2x105 cells at the mammary fat pad, and grown under monitoring over the following 8-10 
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days. Organ harvest was conducted either 24 or 48 h post-injection, depending on the kinetic longevity 
of the nanoparticles in question; all solid organs were rinsed with PBS and dried with lab tissues before 
weighing. Blood samples and whole organ extracts were characterized radiometrically using a gamma 
counter. For Pt nanoparticle quantification, whole organs were digested in concentrated nitric acid and 
processed for ICP-MS by the UNC Department of Chemistry’s Mass Spectrometry Core. 
 For kinetics calculations, mice were assumed to possess a total blood volume of 7.5% total body 
weight. Mean residence time (MRT) was determined via noncompartmental analysis using Phoenix 
WinNonlin (Version 6.3, Pharsight Corporation; Mountain View, CA). The data for PCP incorporating 
PEG2000 was shown to fit well under a two-compartment model through the same software, where 
after the distribution and elimination half-lives were calculated from a linearization of the early and late 
phases of the kinetic profile. 
 For intra-tumor nanoparticle distribution analysis, PCP nanoparticles were formulated with trace 
amounts (1 mol%) of Di-I and subjected to purification through sucrose density gradient centrifugation. 
Briefly, ascending layers of descending sucrose concentration (40%, 20%, and 10%) were produced 
within a high-speed centrifuge tube, where after Di-I-labeled PCP nanoparticles were layered at the top 
of the tube. After 6 hours of centrifugation at 60,000 rpm, nanoparticles were recovered as a separate 
fraction from free micelles, and injected into 4T1 orthotopic tumor-bearing BALB/c mice for 
intratumoral distribution analysis through cryosections (average tumor size: 300 mm3). 
3.3.7: Hepatic Uptake of Fluorescence-Labeled Oligonucleotides Delivered by Fully-PEGylated LCP 
 Fully-PEGylated LCP nanoparticles encapsulating Texas Red-labeled oligonucleotides were 
injected intravenously in 5% glucose to balance osmolarity. After 12 h, livers were harvested and fixed in 
formalin overnight, hydrated in PBS containing 30% sucrose, and frozen in OCT (Tissue-Tek, Dublin, OH). 
Ten micron tissue sections were generated and mounted onto Superfrost Plus slides (Fisher Scientific, 
Houston, TX). Tissue sections were rinsed with PBS and mounted in DAPI-containing medium; actin 
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staining was facilitated prior to addition of mounting medium via FITC-phalloidin staining and 
subsequent washing with PBS. Images were acquired with a Nikon Eclipse Ti fluorescence microscope. 
3.3.8: Hepatic Transgene Expression Through Fully-PEGylated LCP 
 Fully-PEGylated LCP nanoparticles encapsulating RFP plasmid were injected intravenously (0.5 
mg/kg) in 5% glucose to balance osmolarity. After two days, major systemic organs were harvested and 
imaged in standing PBS (to prevent tissue dehydration) under a Perkin-Elmer IVIS imaging system (Santa 
Clara, CA). Livers were then fixed in 4% paraformaldehyde overnight, hydrated in PBS containing 30% 
sucrose, and frozen in OCT (Tissue-Tek, Dublin, OH), after which 10-micron cryosections were processed 
onto glass slides. After mounting in DAPI-containing medium, fluorescence images were acquired with a 
Nikon Eclipse Ti fluorescence microscope. 
3.3.9: Platinum Release through PPC Liposomes 
 PPC nanoparticles were incubated under sink conditions (within a 1 mL cassette possessing a 
semi-permeable membrane (3 kDa) exposed to a 15 mL conical centrifuge tube) with sink replacement 
at each recorded time point at 37°C in PBS for platinum release, with the retentate platinum content 
determined through ICP-MS by the UNC Department of Chemistry’s Mass Spectrometry Core. 
3.3.10: Platinum Bystander Effect In Vitro of PPC Liposomes 
 100 µM Pt, free or encapsulated within LPC or PPC, was incubated with A375 cells for 4 hours, 
after which cells were harvested and co-cultured with naïve A375 cells for 36 hours and imaged with a 
Nikon Eclipse Ti fluorescence microscope set to brightfield. 
3.3.11: Tumor Growth Inhibition Studies 
 A375 melanoma cells (5x106 per mouse) were inoculated s.c. into nude mice on day 0. Mice 
were treated with cisplatin upon generation of a palpable and consistently growing tumor population, 
whether with free drug (CDDP) or cationic (LPC), fully-PEGylated (PPC), or cationic fully-PEGylated (PPC-
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DC) liposomes. Tumor volume was measured every other day by manual calipers, with tumor volume = 
LW2/2, where L is the longest dimension and W is orthogonal to L. 
3.3.12: H&E Staining of Major Systemic Organs 
 Upon completion of (3.3.11), mouse organs were harvested and fixed overnight in 4% 
paraformaldehyde, rinsed under tap water for 1 hour, and delivered in 70% ethanol to the UNC 
Histology Core Facility for paraffin-embedding and tissue sectioning. H&E staining was performed 
according to standard procedures, and images were visualized under a Nikon Eclipse Ti fluorescence 
microscope (set to brightfield exposure). 
3.3.13: Hematological Marker Analysis 
 After treatment with cisplatin, whole blood was recovered in EDTA-coated tubes where after 
serum was recovered under centrifugation. Serum chemistry was analyzed by the UNC Histology Core 
Facility for relevant markers of hepatic and renal toxicity. 
3.3.14: Statistical Analysis 
 Data are presented as Mean ± SD. Statistical significance was defined by P < 0.05 through a two-
tailed t-test when comparing two groups, and the Holm-Sidak test for multiple comparisons. 
3.4: Results: 
3.4.1: Full PEGylation Confers Circulation Longevity in a Chain Length-Dependent Manner 
 Our motivation to increase further the density of PEG on the LCP nanoparticle surface initiated 
in part from previous work with traditional LCP which showed a surprisingly rapid distribution clearance, 
only exhibiting extended circulation longevity after well over half of the injected dose had been 
eliminated from the circulation.26, 30 Further, the LCP nanoparticle system in general, in particular due to 
the novelty in establishing a supported lipid bilayer on the surface of a solid CaP nanoparticle core, has 
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been shown to open up a variety of therapeutics (nucleic acids,26, 28, 29 phosphorylated peptides27 and 
small-molecule prodrugs28) to unilamellar liposomal delivery and foundational efficacy in vivo which are 
exceedingly difficult to load passively within the aqueous core environment of a traditional liposome 
(e.g. Doxil®). Given our particles’ increased PEGylation density on the outer leaflet, as well as the 
improved quality of the formulation (particularly without extensive excesses of outer leaflet lipids or 
extreme formulation conditions such as sonication), we hypothesized that we would be able to reduce 
such rapid distribution clearance and increase the overall systemic exposure to our fully-PEGylated 
formulation. Further, again given our high density of PEGylation, we sought to broaden our efforts in 
exploring the impact of PEG chain length on circulation longevity at these densities with such small 
nanoparticles. 
 After injection via tail vein, BALB/c mice were sampled serially for blood at various time points, 
and sacrificed for whole-organ biodistribution analysis after sufficient clearance from the circulation. 
Figure 3.1 highlights such chain length dependencies on circulation longevity, showing therein a 
proportional relationship. While LCP coated exclusively with PEG350 phospholipids was rapidly cleared 
from the circulation, upon extension of the chain to PEG1000, a two-phase distribution profile emerged. 
Further extension to PEG2000 decreased both the distribution and elimination clearance rates as well, 
with PEG5000 allowing for only a negligible increase in overall exposure. Further, such increases in kinetic 
longevity (a mean residence time of 13 hours for the PEG2000 formulation) correlate as expected to the 
extent of protein adsorption to the nanoparticles (Figure 2.6), which is readily anticipated given the 
marked differences between such formulations in their ability to effectively screen liposome surface 
charge from the surrounding environment (Table 2.1). In contrast to previously published data as well,26 
targeting to the asialoglycoprotein (ASGPR) receptor on hepatocytes through galactose ligands 
(conjugated to the distal chain end of PEG) contributed to an increased distribution clearance without 
80 
 
entirely abrogating nanoparticle long-circulating properties. Thus, full PEGylation can confer meaningful 
circulation longevity proportional to increasing PEG chain length. 
3.4.2: Full PEGylation Resolves Rapid Distribution Clearance Observed with Traditional LCP in a Core 
Size-Independent Manner 
 Of particular interest (as the initial hypothesis which generated this arm of research) to 
development of the PCP particle system remains its performance in comparison to traditional LCP under 
comparable formulation conditions. A particular benefit described in earlier chapters for the PCP system 
is the lack of necessity of sonication in the formulation, and ultimately its projected simplified path to 
translation through solvent displacement-based processing (e.g. ethanol extraction). Therefore, 
comparison of circulation longevity under such conditions was undertaken, with PCP and LCP 
nanoparticles encapsulating both model drug (dsDNA oligos) and 177Lu. Therein, PCP almost fully 
abrogates the distribution clearance which 20 mol% PEG2000-modified LCP possesses, increasing the 
overall systemic exposure to the nanoparticles (Figure 3.2). Further, CaP core size does not meaningfully 
impact nanoparticle circulation or biodistribution properties (Figure 3.3), only slightly favoring splenic 
accumulation over kidney in the case of larger cores (a phenomenon entirely expected based on particle 
core size discrepancies). 
3.4.3: Full PEGylation Confers Stealth in a Chain Length-Dependent Manner, Which can be Refocused 
through Active Targeting 
 These dependencies of circulation longevity on chain length and targeting express themselves 
further through the terminal biodistribution profiles of such fully-PEGylated particles (Figure 3.4). As one 
increases PEG chain length from 350 to 1000 to 2000 Da, dramatic changes in their overall distribution 
to major organs of nanoparticle clearance are apparent. Given their instability in physiological salt and 
serum conditions due to their failure at effective liposome surface charge screening, PEG350-modified 
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LCP exhibit as expected an extensive distribution to the liver, where over half of the injected 
radionuclide accumulates. While PEG1000-modified LCP shows a prolonged elimination clearance and an 
enhanced evasion of uptake within the liver, splenic accumulation predominates at a surprising 304% ID 
per gram tissue; however, such phenomena of dramatic splenic nanoparticle accumulation is not 
entirely unexpected as one progresses into the long-circulation domain.51 It is sufficient, however, at the 
level of PEG2000 modification for LCP to effectively evade uptake in all major clearing organs, instead 
accumulating in bone at anywhere from 10% to 25% ID per gram in our sampling due to the natural 
tropism for free Lu to accumulate therein (such high accumulation, extended across the entire skeletal 
system, corresponds to roughly half of the injected 177Lu dose). To confirm this evaluation 
mechanistically, galactose-PEG2000-modified LCP resolves much of the loss of 
177Lu in this manner, 
refocusing the nanoparticles more specifically to the liver (~50% ID/g, on par with the traditional LCP 
formulation26 through active targeting (in contrast to the passive scavenging of the poorly-shielded 
PEG350 formulation by the liver). The PEG5000 formulation functioned similarly to the PEG2000 formulation, 
with minor accumulation differences potentially owing a causal relationship to the well-considered PEG 
shedding phenomenon, whereby over extended in vivo exposure lipids with an increased ratio between 
PEG and acyl chain length will shed such chains at an increased rate, thus opening up such particles to 
opsonization and immune scavenging despite long-circulating benefits.6, 52 
3.4.4: Full PEGylation Supports Passive Tropism to Primary Hepatocytes and Competitive Transgene 
Expression Absent Cationic Lipids In Vivo 
 Given such improved circulation properties and enhanced stealth supported by such fully-
PEGylated liposomes, we sought to explore the means through which such a particle system may 
support favorable distribution to a variety of therapeutic targets in vivo; namely, both primary 
hepatocytes and solid tumors via systemic delivery, and local as well as systemic lymphatics upon 
subcutaneous administration. In the case of the former, previous studies utilizing LCP PEGylated to low 
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densities (0 mol% to 20 mol%) presented a surprising phenomenon which was found to be independent 
of active targeting: the dramatic alteration in the passive distribution of such nanoparticles locally within 
the liver, showing a shift in tropism with increased PEGylation density beyond 10 mol% from Kupffer 
cells, the resident macrophages of the liver, to uptake within the primary hepatocytes.30 We thus sought 
to explore whether a fully-PEGylated LCP nanoparticle, delivering a Texas Red-labeled oligonucleotide, 
could extend this phenomenon absent any traditional bilayer-forming lipids or active targeting 
strategies. Mice were sacrificed at 12 h post-injection (after extensive clearance of the nanoparticles 
from the circulation), and livers were harvested, fixed, sectioned, and stained with both DAPI (blue) and 
FITC-phalloidin (green) for visualization of nucleus and cytoskeleton, respectively. Indeed, through 
fluorescence imaging of these frozen liver sections (Figure 3.5), we observe a notable delivery of Texas 
Red-labeled dsDNA oligo through the fully-PEGylated formulation; further, such distribution represents 
as a diffuse red fluorescence across the hepatocellular substructures, indicating an effective escape of 
such oligonucleotides from endosomes after internalization. Thus, LCP nanoparticles coated exclusively 
on their outer leaflet by DSPE-PEG2000 can also facilitate comparably hepatocyte-specific delivery at the 
intra-organ level, extending the phenomenon observed through traditional LCP. 
 Given such hepatocyte-specific delivery at the intra-organ level through full PEGylation, with 
rapid and global nanoparticle distribution to the liver through galactose targeting to ASGPR on 
hepatocytes, one can also consider the fully-PEGylated system in the context of hepatic transgene 
expression as described for LCP in previous work.26 Further, the flexibility of the PCP liposome platform 
allows for examination of the effects in vivo of cationic lipids on the efficacy of delivery overall. Mice 
were intravenously administered 10 micrograms of plasmid DNA encoding for red fluorescent protein 
(RFP) through either LCP (incorporating DOTAP) or PCP incorporating either traditional cholesterol (PCP) 
or an ionizable cationic derivative known as DC-Chol (PCP-DC), where after two days major organs were 
harvested for whole organ fluorescence imaging as well as cryosectioning. Representative images 
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(Figure 3.6) show strong and specific hepatic RFP expression across all nanoparticle platforms, despite 
the absence of cationic lipid in the PCP formulation employing traditional cholesterol; such expression 
was further confirmed to be diffuse across liver cryosections. Further, quantification suggests an 
enhanced specificity in transgene expression through PCP, as off-target effects within the kidney are 
somewhat reduced. Therefore, PCP represents a competitive hepatic transgene expression system 
absent cationic lipid. 
3.4.5: Enhanced Stealth Facilitates Preferential Systemic Distribution of Fully-PEGylated Liposomes in 
Tumor-Bearing Mice 
 While galactose, as shown in the previous section, can drive nanoparticle accumulation within 
the liver in a highly targeted fashion, the capable circulation longevity and evasion of traditional organs 
of nanoparticle clearance observed through the PCP liposome system presents a strong opportunity to 
characterize the delivery of such nanoparticles to solid tumors. In this context, BALB/c mice inoculated 
orthotopically with 4T1 breast cancer tumors were administered either PCP or LCP encapsulating 177Lu 
with or without anisamide (AA) ligand modification. Results at 24 hours post-administration again 
highlight the observed stealth effects through full PEGylation, and emphasize a lack of meaningful 
distribution differences between the targeted and untargeted PCP formulations. Further, while tumor 
accumulation differences between PCP and LCP remain minor at best (~2-fold), the extraordinarily off-
target distribution of LCP is highlighted most strongly when building mass-normalized accumulation 
relationships across systemic organs (Figure 3.7). Further, as determined through PCP nanoparticle 
administration containing trace amounts of the lipid marker Di-I, while PCP nanoparticle distribution 
remains heterogeneous within the tumor, meaningful penetration across tissue sections of such 
nanoparticles can be observed in this basic orthotopic syngeneic model. 
 Despite such strong mass-normalized results for the PCP system, such a minor difference in 
relative tumor accumulation necessitated alternative strategies through which to promote a meaningful 
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therapeutic effect in vivo. Therefore, the PPC nanoparticles described in the previous chapter were 
employed, given their capable improvements in dose-dependent cytotoxicity in comparison to free 
cisplatin, providing order-of-magnitude decreases in IC50 while only underperforming against LCP by 
roughly two-fold. Biodistribution analysis of major organ platinum accumulation at 8 hours post-
administration, via inductively-coupled plasma mass spectrometry (ICP-MS), reveals a striking 
recapitulation of the stealth effects observed with full PEGylation of LCP, despite the relative transience 
of cisplatin in comparison to the cumulatively-distributed 177Lu. In contrast to the strong accumulation 
within liver and spleen on a mass-normalized basis for the LPC system, PCP facilitates an even 
distribution across all major systemic organs of nanoparticle clearance (liver, spleen, kidneys, and lung); 
quantification within mice for each particle group reveals a 21-fold decrease in accumulation deviation 
between such clearing organs (Figure 3.8). Further, in projecting therapeutic response in terms of in vivo 
accumulation of cisplatin within tumors through IC50 measurements derived from in vitro cytotoxicity 
studies, at the 2 mg/kg dosing level employed within this study, both PPC and LPC remain well above 
such concentrations. Therefore, PPC represents a capable stealth property in its own right which can be 
harnessed for meaningful therapeutic accumulation within solid tumors in vivo. 
3.4.6: Neighboring Effects Mediated By Cisplatin Release Underlie PPC Therapeutic Response In Vivo 
 Previous studies have shown a strong bystander effect for the LPC nanoparticle system both in 
vitro and in vivo; briefly, both cellular apoptosis (as measured by TUNEL) and CDDP-DNA adduct 
formation (as measured by IHC) do more than simply coincide in the local neighborhood of LPC 
nanoparticles (determined by Di-I accumulation) within solid tumors in vivo – the magnitude of such 
responses is shown to fall off exponentially in terms of nearest-neighbor distance of such events from 
the cells in which LPC particles accumulate.31 This phenomenon has in the same work been re-created at 
the in vitro level through co-culture experiments; herein, we confirm as well that PCP not only facilitates 
an enhanced dose-dependent cytotoxicity in vitro, but also recapitulates the potent bystander effect 
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which cisplatin can mediate, as a co-culture of only 8% cells exposed to 100 µM PPC for 4 hours (i.e. 92% 
naïve cells) remains sufficient to effectively abrogate any cell growth within the culture (Figure 3.9). 
Further, the gradual (but not burst) release of cisplatin (on the order of hours) from PPC again 
recapitulates a means of cisplatin exposure within the tumor. 
 Given such diverse and capable pharmaceutic performance through the PPC nanoparticle 
system, its therapeutic potential was explored in an in vivo model of melanoma (A375). Mice were 
administered either saline control or 1.5 mg/kg cisplatin, whether free (CDDP) or particle-based (LPC, 
PPC), over 4-6 day dosing intervals (four doses in total), and tumor growth was monitored via standard 
caliper-based methods. Interestingly, PPC exhibited statistically significant inhibition of tumor growth in 
comparison to not only saline and CDDP controls, but to the LPC system as well (Figure 3.11). Despite 
such success however, observation of the overall tumor growth over the course of the study reveals a 7-
fold increase in tumor size within the PPC group (in comparison to roughly 13-fold for the other groups); 
while statistically significant, such a response remains poor in overall magnitude. Therefore, we 
explored further potential toxicities which such therapies may mediate at a number of levels within 
these mice. First, all of the mice were observed to gain weight over the course of the study (Figure 3.11). 
Second, histological analysis revealed no major organ toxicities within these mice (Figure 3.12). And 
lastly, in contrast to transient kidney toxicities at relatively high doses of cisplatin (decreased serum 
Creatinine observed in Table 3.1), the multiple dosing strategy employed herein lacked any meaningful 
impact upon liver and kidney serum chemistry parameters (Table 3.2). Thus, it can be inferred that the 
previous study was performed at relatively non-toxic therapeutic conditions. To follow up such work, a 
slightly more aggressive treatment regimen was established (2 mg/kg, q4d, 3 total injections) in a 
separate experiment, with tumor growth monitored as before. In this case, while maintaining body 
weight gain across all treatment groups over the course of the study, PPC again facilitated statistically 
significant inhibition of tumor growth, but was more effectively able to slow disease progression and 
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extend such effects beyond the range of the treatment interval (Figure 3.13). Therefore, PPC represents 
as effective in such a proof-of-concept therapeutic strategy. 
 However, included within this study as well was a separate group, PPC-DC, which represents a 
particle structurally equivalent to PPC, but instead incorporating the ionizable cationic lipid DC-Chol in 
place of cholesterol (such particles hold an equivalent relationship to the PCP and PCP-DC particles 
described in section 3.4.4). Shockingly, over an interval of 1-2 days after the second nanoparticle 
administration, four of the five mice in the PPC-DC group died, despite a lack of mouse weight loss after 
the first injection, a lack of noticeable behavior changes in the mice upon the second injection, a lack of 
formulation difference or quality between the PPC and PPC-DC systems, and dosing which remains well 
below the MTD for both cisplatin within the core and DC-Chol on the surface. Given each of these 
considerations, and the lack of toxicity observed in the PPC system, it is reasonable to determine that 
the toxicity is mediated by the inclusion of DC-Chol within the nanoparticle formulation, despite its 
nature as a purportedly safer ionizable cationic material. 
3.5: Discussion 
 While the fully-PEGylated liposomes described herein were expected to hold promise for 
enhanced pharmaceutics properties which, when coupled with competitive functional performance, can 
contribute to an enhanced therapeutic effect, the in vivo translation of such particles has met or 
exceeded expectations at the outset. In particular, our ability to broadly characterize nanoparticle 
stealth through terminal 177Lu distribution analysis, rather than simple kinetic longevity, lends strength 
to our conclusions in contrast to studies which equivocate between the terms “stealth” and “long-
circulating.” Given the natural bone tropism for free Lu, in essence, such a radionuclide tracer serves a 
dual benefit of tracking a truly particle-specific and cumulative distribution. As such, we can clearly 
observe that, despite the extended elimination half-life of the PEG1000-modified PCP nanoparticles, no 
meaningful “stealth” can be attributed to what quantitatively represents a mere shift in nanoparticle 
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accumulation from liver to spleen; it is only at the PEG2000 level where meaningful avoidance of clearing 
organs can be observed. If observed simply at the kinetic level, however, the AUC differences between 
such formulations (roughly two-fold) offer much less functional insight in this regard. Further, not only 
does PCP abrogate entirely the distribution clearance observed with LCP, extending the kinetic profile 
into a first-order domain with a mean residence time (MRT) of 13 hours and a half life (t1/2) of 9 hours, 
the stealth property it provides in avoiding traditional organs of nanoparticle clearance is fundamentally 
greater than any previous observation made with the LCP nanoparticle system. Such stealth provides 
the basis as well for particle-specific accumulation within the orthotopic, syngeneic 4T1 tumor model 
employed herein: while accumulation differences are minor at best between PCP and LCP (~2-fold), the 
dose-normalized accumulation compared to clearing organs for PCP yields dramatic benefits in a general 
consideration of the toxicity risks which off-target delivery can pose. 
 Nevertheless, functional efficacy remains the benchmark on which PCP as a formulation basis 
will rest, beyond its obvious (and thus of minimal exploratory interest) distributive benefits regarding 
diagnostic imaging modalities. In this context, the clear and present deviation of PCP from LCP is the loss 
of the cationic lipid DOTAP from the formulation, whose function in endosome escape as a reverse-
hexagonal bilayer disrupting agent is well-known in the field,6 and any consideration of rational 
therapeutic strategy design thereafter must consider its potential implications. For example, it is 
described herein that, despite the lack of such cationic lipid in the formulation, PCP remains competitive 
in the degree of hepatic transgene expression produced in delivering the plasmid DNA and cationic 
peptide complex pRFP/CR8C to primary hepatocytes in a galactose ligand-bearing formulation. The 
benefits of CR8C in nuclear localization have been described in previous work,26 and are not within the 
scope of inquiry herein; however, it is important to consider the degree of focused delivery which can be 
achieved through both LCP and PCP. Previous studies have shown a greater degree of fluorescent 
oligonucleotide delivery to the liver by LCP which incorporates DOTAP as compared to DOPC, a neutral 
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bilayer-forming lipid in charge; however, such increases cannot be assumed to be driven exclusively by 
an enhanced endosome escape functionality of DOTAP, as there remain dramatic differences in 
biodistribution to the liver between the two formulations (60% and 30% for DOTAP- and DOPC-
possessing LCP, respectively).30 Thus, it is important to remember that the global biodistribution of PCP, 
which innately possesses tropism toward primary hepatocytes for similar fluorescent oligo delivery 
(Figure 3.5), can be shifted dramatically from its intrinsic 10-20% ID to 50-60% through ASGPR targeting 
via galactose ligand modification of the PEGylated surface (Figure 3.4). Thus, what can be essentially 
achieved through galactose-bearing PCP, in much the same way as LCP, is a relative flooding of the liver 
with nanoparticle, rapidly, extensively, and in a cell uptake-driven capacity, as roughly 90% of the 
recovered nuclide in the biodistribution experiment for the PEG-GAL group located within the liver. Such 
conditions relate logically to the in vitro uptake of PCP observed in the previous chapter (Figure 2.12), 
wherein effective dissociation of fluorescent oligo from fluorescent inner-leaflet lipid over micron scales 
conveys effective endosome escape in the absence of cationic lipid. In short, under conditions of 
extensive local nanoparticle exposure, the osmotic bursting effect which forms the basis of the calcium 
phosphate core’s contribution to endosome escape likely becomes sufficient for mediation of efficacy, 
leading to the competitive transgene expression observed herein (Figure 3.6). 
 However, such logic should by no means be extended without reason to all therapeutic 
strategies in vivo. In the case of nanoparticle delivery to solid tumors, nanoparticle exposure overall 
remains orders of magnitude below that which is experienced within the liver in these studies. Even on a 
mass-normalized basis, nanoparticle accumulation remains highly dependent upon (i.e. highly variable 
between) tumor size and model (Figures 3.7 and 3.8) as well as the relative desmoplastic nature of the 
tumor itself.32 As can be seen in a moderately-sized (200 mm3) yet relatively conventional melanoma 
model (subcutaneous A375, Figure 3.8), even mass-normalized drug accumulation can be over an order 
of magnitude less than that which is experienced through hepatic delivery of PCP-GAL. It is well-known 
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in the field that, despite the ability to overcome the need of cationic lipid under in vitro conditions, it is 
in the minute delivery to solid tumors experienced in vivo where such lipids exert their fundamental 
advantage.6 Therefore, rational employment of full liposome PEGylation for efficacy within solid tumors 
demands an improved design. 
 It would be simple to propose at this stage of discussion to utilize a cationic or even ionizable 
cholesterol within the PCP formulation, as it bears comparable charge to DOTAP while contributing only 
minor (but not negligible) surface area occupancy to the lipid bilayer. Indeed, such a proposition holds 
value, and we explore its value in a variety of considerations herein. However, such an approach 
remains rather disappointing academically, in making extensive fundamental efforts to formulate a 
liposome devoid of DOTAP or any other un-PEGylated, bilayer-forming lipid, only to concede to the need 
for related lipids at the moment when functional efficacy is desired. A far more interesting strategy 
explores the need for such cationic lipids at all, employing a rational selection of nanoparticle cores 
through which competitive (or even improved) efficacy can be achieved. This essentially outlines the 
rationale for selection of the DOPA-coated pure cisplatin nanoparticle (Pt) cores for full PEGylation (PPC) 
for delivery to solid tumors. As observed in the previous chapter, PPC performs comparably to LPC in 
vitro in mediating dose dependent cytotoxicity (~2-fold difference), performing at orders of magnitude 
increased potency as compared to free cisplatin. Though cisplatin is thought of as highly insoluble under 
either aqueous or organic conditions, when precipitated at the nanoscale, it is shown herein (Figure 3.9) 
as well as previously31 to exhibit a slow but non-burst release profile, allowing for both extracellular and 
intracellular exposures to platinum drug. However, the potency of cisplatin lies most interestingly in its 
ability to mediate bystander toxicity to neighboring cells which do not participate in the particle uptake 
process. As shown herein in vitro, this essentially means that co-culture of even just 8% of cells having 
internalized cisplatin nanoparticles with 92% naïve cells remains sufficient to yield apoptosis across the 
entire population of cells. Therefore, the ability herein to employ a delivery strategy wherein the 
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cytotoxic power of the formulation lies relatively independent of cationic lipid necessities allows for 
functional efficacy in tumor growth inhibition absent such cationic lipids. Further, as can be seen from 
the deaths of 4/5 mice in the PPC-DC nanoparticle group, even ionizable cationic lipids should not be 
asserted as a panacea solution to cationic lipid-mediated toxicity, a well-described problem in previous 
literature.6 
3.6: Conclusions 
 In this work, we present the enhanced systemic delivery capabilities of fully-PEGylated liposomal 
nanoparticles in vivo, focusing upon delivery to both liver and tumor. Such PCP liposomes exhibit a PEG 
chain length-dependent circulation longevity and stealth property in biodistribution that is independent 
of nanoparticle core size, outperforming the traditional LCP nanoparticle system in abrogation of rapid 
distribution clearance upon intravenous injection. Major organ biodistribution of these PCP liposomes 
shows a chain length-dependent stealth evasion of traditional organs of nanoparticle clearance as well, 
which can be resolved completely through simple active targeting mechanisms, and facilitates dose-
normalized accumulation ratios between tumor and liver or spleen in excess of that of LCP. At the 
PEG2000 level, the highest performing of the chain lengths tested, PCP facilitates the PEG density-
dependent passive tropism to primary hepatocytes observed in previous studies, and in an ASGPR-
targeted mechanism, can support competitive degrees of transgene expression within the liver with 
minimal off-target effects absent any cationic lipid in formulation. In terms of delivery to solid tumors, 
the enhanced neighboring effect of the Pt nanoparticle core platform can be leveraged in the same 
manner to facilitate meaningful tumor growth inhibition absent cationic lipid, and in a non-toxic 
multiple-dosing regimen of platinum in contrast to that with even ionizable cationic lipid. Given these 
results, PCP represents a competitive, cation-free formulation basis for mediating therapeutic effect in 





Figure 3.1: Systemic Kinetics of PCP Liposomes. CaP precipitates encapsulating trace amounts of 177Lu 
were modified exclusively with PEGylated phospholipids of varying chain length and targeting 
capabilities, and administered via tail vein to BALB/c mice, with kinetics monitored serially and 
















Figure 3.2: PCP Abrogates the Rapid Distribution Clearance of LCP. LCP nanoparticles encapsulating 
both 177Lu and oligonucleotides were injected via tail vein into BALB/c mice and monitored 














Figure 3.3: Biodistribution of PCP Liposomes of Variable CaP Core Diameters. PCP liposomes 
encapsulating 177Lu were injected i.v. into BALB/c mice (n=3) and sacrificed 24 h post-injection for 














Figure 3.4: Biodistribution of Fully-PEGylated LCP Liposomes Exhibits Chain Length-Dependent Stealth. 
CaP precipitates encapsulating trace 177Lu were modified exclusively with PEGylated phospholipids 
(DSPE) of varying chain length and targeting and administered i.v. to BALB/c mice (n = 4), with organs 
















Figure 3.5: PCP Exhibits Passive Tropism to Primary Hepatocytes In Vivo. DSPE-PEG2k-modified PCP 
encapsulating oligonucleotides labeled with Texas Red were administered via tail vein. 12 h later, 
BALB/c mouse livers were harvested and frozen sections were prepared for imaging. Green = FITC-
phalloidin stain. Blue = DAPI. Images: 0.125 mg/kg Texas Red oligo (A) without and (C) with actin 











Figure 3.6: PCP Exhibits Competitive In Vivo Hepatic Gene Expression Absent Cationic Lipid. Mice were 
administered i.v. 10 µg of RFP pDNA complexed with CR8C peptide through either the LCP 
(incorporating DOTAP) or PCP (Chol or DC-Chol) GAL-targeted particle systems. Two days after 
injection, organs were harvested for visualization through (A) cryosection fluorescence imaging and 
(B) IVIS. Image quantification represents autofluorescence-subtracted radiance from liver and kidneys. 














Figure 3.7: LCP Biodistribution in Tumor-Bearing Mice. BALB/c mice were inoculated orthotopically 
with 4T1 tumors, and biodistribution of fully-PEGylated LCP containing 177Lu was determined at 24 
hours post-i.v. injection. Average tumor size = 100 mm3 (n = 3-4). DiI distribution (PCP) was evaluated 















Figure 3.8: LPC Biodistribution in Tumor-Bearing Mice. Nude mice were inoculated with A375 cells, 
and biodistribution of fully-PEGylated LPC was determined at 8 hours post-tail vein injection by ICP-
MS. Average tumor size ~200 mm3 (n = 3). Relative tumor IC50 was derived from the previous MTT 
















Figure 3.9: Platinum Release and Uptake through PPC. PPC nanoparticles were incubated under sink 
conditions with replacement at 37°C in PBS for platinum release, or uptake into A375 cells over 3 















Figure 3.10: Platinum Bystander Effect through PPC. 100 µM Pt was incubated with A375 cells for 4 
hours, after which cells were harvested and co-cultured (8%) with naïve A375 cells (92%) for 36 hours 













Figure 3.11: Tumor Growth Inhibition via Platinum Nanoprecipitate Liposomes. A375 melanoma cells 
(5x106 per mouse) were inoculated into nude mice on day 0. Mice were treated with 1.5 mg/kg of 
cisplatin (arrows), whether free drug (CDDP), or cationic (LPC) or fully-PEGylated (PPC) NPs. Tumor 

















Figure 3.12: Major Organ H&E Staining. Mice were treated with cisplatin 4 times at 1.5 mg/kg (q5d), 














T-3.1 LPC PPC CDDP 95% CI 
BUN 
(mg/dL) 
21 ± 1 25 ± 4 17 ± 3 17-38 
Creatinine 
(mg/dL) 
0.33 ± 0.02 0.31 ± 0.11 0.26 ± 0.04 0.3-0.5 
ALT 
(U/L) 
18 ± 6 14 ± 4 11 ± 1 35-90 
AST 
(U/L) 
107 ± 16 117 ± 37 104 ± 30 63-253 
Table 3.1: Liver and Kidney Function under Transient Platinum Exposure. Mice were treated with 3 
mg/kg of cisplatin, either free (CDDP) or particle-based (LPC, PPC). 24 hours post-i.v. injection, mice 
were sacrificed and serum harvested for clinical chemistry analysis. Yellow indicates borderline 












T-2.3B PBS CDDP LPC PPC 
BUN 
(mg/dL) 
27 ± 5 28 ± 3 27 ± 6 27 ± 3 
Creatinine 
(mg/dL) 
0.48 ± 0.06 0.53 ± 0.10 0.55 ± 0.10 0.50 ± 0.04 
ALT 
(U/L) 
8 ± 6 16 ± 4 14 ± 9 16 ± 4 
AST 
(U/L) 
85 ± 23 174 ± 97 136 ± 59 116 ± 46 
Table 3.2 Liver and Kidney Function under Repeated Platinum Exposure. Mice were treated with 1.5 
mg/kg of cisplatin, either free (CDDP) or particle-based (LPC, PPC) every 5 days. 5 days after the 4th 














Figure 3.13: Tumor Growth Inhibition via Platinum Nanoprecipitate Liposomes. A375 melanoma cells 
(5x106 per mouse) were inoculated into nude mice on day 0. Mice were treated with 2 mg/kg of 
cisplatin (arrows), whether free drug (CDDP), or cationic (PPC-DC) or fully-PEGylated (PPC) NPs. Tumor 
volume = LW2/2; n = 5 per group; *p<0.05, **p<0.02 compared with PPC. Four of 5 mice in the PPC-DC 
















CHAPTER 4: FULLY-PEGYLATED LIPOSOMES FOR ENHANCED LOCAL DELIVERY 
4.1: Summary 
 Novel liposomes densely coated exclusively with PEGylated phospholipids (PCP, PPC) have been 
developed, through exploitation of the supported bilayer phenomenon, which exhibit effective stealth 
properties in ex vivo studies while improving cell uptake and therapeutic function in vitro in comparison 
to traditional formulations. In this work, we present the enhanced local delivery capabilities of such 
nanoparticles in vivo, focusing upon delivery to draining lymphatics upon subcutaneous injection. These 
PCP liposomes exhibit an enhanced accumulation within local lymph nodes which is largely driven by 
PEGylation density rather than active targeting to immune cells, with absorption rate and systemic 
exposure differences underlying such expectations for improved lymphatic drainage. However, despite 
high distributive accumulation, limited internalization into cells through even active targeting strategies 
likely precludes comparable therapeutic effects in terms of measurable immune response. Therefore, 
we present a new derivative formulation based on the LCP nanoparticle platform, but instead utilizing 
magnesium phosphate as a nanoparticle core, which aims to resolve such limitations. These PMP 
nanoparticles exhibit a decreased propensity toward aggregation which contributes to an enhanced 
lymphatic distribution, as well as a more rapid rate of degradation at endosomal pH which can 
contribute to osmotic swelling and release therein. As such, PMP can effectively salvage formulation 
function in vivo in generating an antigen-specific, CTL-activating immune response. Thus, magnesium 
expands, along with calcium- and platinum-based nanoparticle cores, the library of potential 
pharmaceutic modalities which can be employed in the lipid-coated nanoprecipitate platform for 




 In the previous chapters, full PEGylation of a spontaneously self-assembled liposome outer 
leaflet was described for the first time, exhibiting ex vivo, in vitro, and in vivo stealth properties as well 
as  pharmaceutic and therapeutic performance either competitive with or in excess of the traditional 
LCP liposomal nanoprecipitate formulations at 20 mol% PEGylation. In brief, observations include (at the 
level of PEG2000 modification) a prolonged nanoparticle circulation, abrogation of rapid distribution 
clearance, and a best-in-class stealth evasion of traditional organs of nanoparticle clearance; an 
improved distribution profile to solid tumor through passive targeting and primary hepatocytes through 
both passive and active targeting; an enhanced internalization into cells along with capable escape from 
endosomal entrapment; and competitive therapeutic responses in terms of both hepatic gene 
expression and platinum-based tumor growth inhibition. Given such successes under conditions of 
systemic delivery, alternative routes of administration in which the LCP platform has shown promise 
were sought out for potential comparative benefits as well. 
 Previous studies have explored both the diagnostic25 and therapeutic27 potential of LCP as a 
lymphatic delivery system, in particular in the context of immune activation (primarily induction of a 
cytotoxic T lymphocyte, or CTL, response) for cancer therapy. Therein, LCP in general terms employs 
both a peptide-based antigenic sequence derived from the tumor in question, as well as an immune-
stimulating pro-inflammatory adjuvant (most often CpG), within the nanoparticle core for delivery to 
professional antigen-presenting cells (APCs) in vivo upon subcutaneous injection. After internalization 
into such cells, CpG adjuvant can exert its stimulating effects through endosomal interaction with toll-
like receptor 9 (TLR9), which recognizes such unmethylated sequences, and cytosolic loading of antigen 
onto MHC class I presentation complexes through which APCs can stimulate T-cells for antigen-specific 
clonal expansion as CTL. Thus, a simplified context of relevant delivery for such therapeutics at the 
nanoscale would involve three basic concepts: effective distribution of such nanoparticles to the APCs of 
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interest, strong uptake and degradation of such nanoparticles within endosomal subcompartments of 
APCs for adjuvant stimulation, and effective endosomal escape of antigenic peptide for loading onto 
MHC-I and subsequent presentation. Herein, we present the enhanced local delivery capabilities of such 
nanoparticles in vivo, focusing upon delivery to draining lymphatics upon subcutaneous injection. These 
PCP liposomes exhibit an enhanced accumulation within local lymph nodes which is largely driven by 
PEGylation density rather than active targeting to immune cells, with absorption rate and systemic 
exposure differences underlying such expectations for improved lymphatic drainage. 
 However, despite high distributive accumulation, limited internalization into cells through even 
active targeting strategies likely precludes comparable therapeutic effects in terms of measurable 
immune response. Therefore, we present a new derivative formulation based on the LCP nanoparticle 
platform, but instead utilizing magnesium phosphate as a nanoparticle core, which aims to resolve such 
limitations. These PMP nanoparticles exhibit a decreased propensity toward aggregation which 
contributes to an enhanced lymphatic distribution, as well as a more rapid rate of degradation at 
endosomal pH which can contribute to osmotic swelling and release therein. As such, PMP can 
effectively salvage formulation function in vivo in generating an antigen-specific, CTL-activating immune 
response. Thus, magnesium expands, along with calcium- and platinum-based nanoparticle cores, the 
library of potential pharmaceutic modalities which can be employed in the lipid-coated nanoprecipitate 
platform for rational therapeutic delivery. 
4.3 Materials and Methods: 
4.3.1: Materials 
 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[succinyl(polyethylene glycol)-2000] 
(DSPE-PEG2000-NHS) was purchased from NOF corporation (Tokyo, Japan). DSPE-PEG2000-mannose 
(MAN) was synthesized following previously described protocols26, 27, 44 and analyzed via NMR using a 
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Varian Inova 400 MHz NMR spectrometer (Palo Alto, CA). All other lipids, including fluorescently-labeled 
lipids, were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). 177Lu was purchased from Perkin-
Elmer (Waltham, MA). Phosphorylated peptide antigen (pSpSSPSYAYHQF, or pAH1-A5) as well as 
standard peptide antigen (SPSYAYHQF, or AH1-A5) were purchased from Peptide 2.0 (Chantilly, VA) as a 
custom product. Iodination tubes and dialysis membrane cassettes (Slide-A-Lyzer) were purchased from 
Thermo Fisher (Grand Island, NY). P2 desalting columns were purchased from Harvard Apparatus 
(Holliston, MA). All other reagents, including fluorescently-labeled and CpG oligonucleotides, were 
purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. Bench-top 
photographs were taken with an iPhone SE camera. 
4.3.2: Cell Lines 
 One cell line was used in the experiments described below: JAWS-II mouse dendritic precursor 
cells (intermediately-differentiated monocytes). 
4.3.3: Experimental Animals 
 Six- to eight-week-old BALB/c female mice were purchased from Charles River Laboratories 
(Wilmington, MA). All work performed on animals was in accordance with and approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
4.3.4: Preparation and Characterization of Fully-PEGylated LCP Nanoparticles 
 Fully-PEGylated LCPs (or LMPs) were prepared using a modified protocol.30, 34 Briefly, two 5 mL 
3:7 Igepal co-520:Cyclohexane w/o microemulsions were prepared – one with 150 µL dibasic 
ammonium phosphate (50 mM), the other with 150 µL calcium (or magnesium) chloride (2.5 M, with or 
without soluble antigen and adjuvant). Emulsions were stirred for 10 min, mixed together, and stirred 
for an additional 10 min, followed by addition of 62.5 µL DOPA (35 mM). After an additional 30 min of 
stirring, the mixture was washed repeatedly with absolute ethanol under centrifugation (10,000 g) to 
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yield a precipitate purified from the excess surfactants. The precipitate was then resuspended in 
chloroform and centrifuged once more (10,000 g) to purify the DOPA-coated CaP cores (supernatant) 
from more poorly-formed nanoprecipitates (pellet). Encapsulation was characterized radiometrically 
using a gamma counter (the Nucleus, Oak Ridge, TN) or through a fluorescence method. 
 CaP cores were then mixed with an excess of outer-leaflet lipids in chloroform (about 2.5- to 5-
fold, depending on the degree of aggregation experienced in resuspension), dried under nitrogen, and 
resuspended at 65°C under aqueous conditions (beginning with absolute ethanol and titrating to < 20% 
with additional DI water). Cholesterol was added to the preparation, particularly for larger nanoparticle 
cores, in order to improve dispersion in rehydration, and comparative studies between PCP and LCP 
involved equimolar proportions of bilayer-forming lipids (in the case of CaP nanoparticles, DOTAP and 
DSPE-PEG). Due to high nanoparticle concentrations in formulation, sonication may be employed as 
needed to maintain a well-dispersed nanoparticle suspension. 
 For encapsulation efficiency characterization, CpG oligo adjuvant was benchmarked by a 
fluorescently-labeled oligo analogue and characterized fluorometrically. pAH1-A5 encapsulation was 
characterized radiometrically through mass balance of iodine-125 labeled at the benzyl groups of 
tyrosine within the peptide. For labeling, iodine was activated as an electrophile using surface-coated 
iodination tubes following the provided protocol with the product, after which peptides were purified 
once through P2 desalting columns following the provided protocol with the product.  
4.3.5: Pharmacokinetics and Biodistribution of Fully-PEGylated LCP Nanoparticles 
 BALB/c mice were injected subcutaneously (local to the right inguinal lymph node) with 
nanoparticle suspensions (supplemented with 5% glucose to balance osmolarity). For kinetics studies, 
blood samples were extracted serially via tail clip, with the final time point obtained via cardiac 
puncture. Organ harvest was conducted either 6, 24, or 72 h post-injection, depending on the kinetic 
longevity of the nanoparticles in question; all solid organs were rinsed with PBS and dried with lab 
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tissues before weighing, taking care in particular with lymph nodes to remove connective tissues which 
could meaningfully bias mass-normalized radiometric calculations. Blood samples and whole organ 
extracts were characterized radiometrically using a gamma counter. For kinetics calculations, mice were 
assumed to possess a total blood volume of 7.5% total body weight. 
4.3.6: PCP and PMP Stability in Aqueous Conditions 
 CaP and MgP cores were resuspended effectively with DSPE-PEG2000 conjugates, stored at 4°C, 
and monitored daily for changes in nanoparticle size distribution by DLS. 
4.3.7: Drug Release from PCP and PMP in Aqueous Sink Conditions 
 Nanoprecipitate liposomes comprising cores of either magnesium (LMP) or calcium (LCP) 
phosphate, encapsulating trace amounts of 177Lu were dialyzed against either 150mM pH 5.9 sodium 
citrate (5.9) or 150 mM pH 7.5 Tris-HCl (7.5) through a 3.5K MWCO membrane (Slide-A-Lyzer), replacing 
the filtrate at each time point. 
4.3.8: Cell Uptake of PCP and PMP. Nanoparticles encapsulating Texas Red-labeled oligonucleotide 
were incubated with JAWS-II cells in vitro in complete medium for 2 hours, after which cells were 
imaged with a Nikon Eclipse Ti fluorescence microscope. 
4.3.9: Interferon Activation and In Vivo CTL Activity Analysis 
 BALB/c mice were first vaccinated with 40+8 µg of AH1-A5+CpG (either as free drug or within 
nanoparticles) by subcutaneous injection local to the right inguinal lymph node. After one week, naïve 
mice (not vaccinated) were sacrificed, in a population 1/3 of that of the vaccinated mice, and spleens 
were harvested and digested in collagenase-containing media (1 mg/mL) for 45 minutes at 37°C. 
Individual splenocytes were then harvested by passage through 70-µm filters, and washed repeatedly 
through ACK buffer incubation cycles in order to remove red blood cells. After sufficient lysis (2-4 
cycles), cells were incubated for 1.5 hours at 37°C in PBS with 40 µg/mL of either active (AH1-A5) or 
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control (β-gal) antigen for surface presentation, gently mixing the cells every 30 minutes to disturb 
settling and ensure an even peptide coating. After washing cells with PBS, cells were then incubated in 
PBS at 37°C for 30 minutes with either 10 µM (labeled “Hi,” for AH1-A5-coated cells) or 2 µM (labeled 
“Lo,” for β-gal-coated cells) CFSE, gently mixing cells every 5-10 minutes to disturb settling and ensure 
an even staining. Remaining CFSE was then quenched with culture medium containing 10% FBS, and 
cells were washed three times with PBS. Equal volume aliquots of Hi and Lo cell mixtures were run 
through flow cytometry to determine the proportion of Hi/Lo, such that when mixing the bulk Hi and Lo 
phases together, the proportion would be 1/1. After mixing, vaccinated as well as control mice were 
injected intravenously with labeled naïve splenocytes for subsequent deposition within the spleen. At 
this point, ELISpot plates were coated with antibody against IFN-γ in PBS and incubated at 4°C overnight 
as well. 
 After 18-24 hours, vaccinated and control mice were sacrificed, and draining inguinal lymph 
nodes as well as spleens were harvested. Organ digestion, dissociation, and ACK washes proceed as 
described previously, where after lymphocytes and splenocytes were incubated in ELISpot wells with 7.5 
µg/mL AH1-A5 antigen in 200 µL culture medium supplemented with 10% FBS at a density of 105 cells 
per well at 37°C overnight. Harvested splenocytes were also analyzed via flow cytometry for relative 
Hi/Lo cell population homing within the spleen via flow cytometry. 
 After 18-24 hours, cells were aspirated from the ELISpot plate, and plates were processed 
further according to provided product protocols. 
4.3.10: Statistical Analysis 
 Data are presented as Mean ± SD. Statistical significance was defined by P < 0.05 through a two-





4.4.1: Full PEGylation Improves Lymphatic Distribution over Traditional LCP 
 With complete PEGylation of the outer leaflet in our novel formulation, we anticipated an 
improved lymphatic drainage and accumulation over time upon subcutaneous administration,25 as a 
logical extension of phenomena observed in traditional liposomal PEGylation53 as well as alternative 
particle systems such as dendrimers (which in particular exhibit a decreased systemic and increased 
lymphatic distribution with both an increase in particle size and PEGylation).54 Therefore, BALB/c mice 
were injected s.c. with either 100 mol% or 20 mol% PEGylated CaP particles in a 5% glucose solution, 
each targeted with 20% of the total DSPE-PEG2000 functionalized as mannose-modified DSPE-PEG2000, and 
major organs were harvested after 6 and 24 h to characterize particle accumulation within major organs. 
Though systemic kinetic absorption was not detectable for such formulations, accumulation for the 
fully-PEGylated nanoparticles (Figure 4.1) within the draining lymph node was increased over six-fold 
(970% vs. 150% ID per gram tissue), suggesting but still requiring further analysis of an improved 
lymphatic drainage capability. Surprisingly, however, the fully-PEGylated yet untargeted formulation 
exhibited significant accumulation within systemic lymphatics, (specifically, within the contralateral 
lymph node to the injection site), implying meaningful absorption characteristics absent local 
internalization. Therefore, to compare with the glucose-balanced particles, we instead prepared an 
osmotically-balanced preparation in 10% sucrose, intended for the partial inhibition of clathrin-
mediated endocytosis local to the injection site. Indeed, we can observe dramatic absorption of both 
formulations within the systemic circulation in this capacity, a recapitulation of the lymphatic 
accumulation contralateral to the injection site, and a consistent maintenance of the differential 
accumulation within the draining inguinal lymph node between 20 and 100 mol% PEGylated 
formulations (Figures 4.2 and 4.3), emphasizing the impact of targeting on particle distribution in vivo. In 
quantifying the kinetic process at hand, we can see further the statistical significance in both absorption 
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rate and systemic exposure (AUC), with PCP providing an increased rate and decreased exposure which 
is characteristic of similar highly-PEGylated and lymphatically-draining nanoparticles such as 
dendrimers.54 Thus, full PEGylation can confer effectively an enhanced lymphatic accumulation of 
liposomal nanoprecipitates upon subcutaneous injection. 
4.4.2: Magnesium Phosphate Cores Show Decreased Aggregation and Rapid Drug Release 
 Given favorable stealth properties observed in systemic delivery as well as competitive 
therapeutic performance, we next desired to build upon the enhanced local delivery of PCP to draining 
lymph nodes upon subcutaneous administration. However, preliminary experiments revealed LCP to 
remain superior to PCP in terms of in vivo antigen-specific cytotoxic T-lymphocyte (CTL) activation; such 
results are not entirely unexpected, given the observed reduction in active particle internalization in 
dendritic cells as compared with tumor cells or hepatocytes. Therefore, to enhance particle performance 
locally in vivo, alternative strategies were explored. 
 Magnesium phosphate represents a well-studied drug and gene delivery platform in its own 
right,55 but involves many of the same limitations for in vivo delivery as experienced with calcium 
phosphate.6 However, formulation of DOPA-coated magnesium phosphate cores (MgP) within the dual 
microemulsion system employed for LCP and PCP formulation follows as entirely straightforward; we 
present such particles herein for the first time as well (PMP, Figure 4.4). Under formulation conditions 
exactly as in the CaP core system, antigen (pAH1-A5, a derivative of the AH1-A5 peptide SPSYAYHQF 
which includes two extra phosphatidylserine residues at the N-terminus, modification which has been 
shown previously to be inconsequential in terms of base peptide antigenicity27) and adjuvant (CpG 
oligonucleotide, a TLR9 agonist) can also be loaded at a 5:1 ratio with encapsulation efficiency for both 
materials ranging from 60-70%, while particle quality as assessed through TEM and DLS measurements 
remains consistent with previous formulations. Moreover, PMP exhibit stability in solution over multiple 
days (Figure 4.5) as well as a more rapid release at endosomal pH (Figure 4.6), respectively suggesting a 
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slightly improved distributive profile upon subcutaneous administration and an enhanced capacity for 
endosome disruption via the osmotic bursting phenomenon. 
4.4.3: PMP Stability and Release Drives Lymphatic Accumulation and Cellular Uptake 
 As MgP cores represent a functionally superior platform to CaP ex vivo, we sought to explore the 
impact of such performance upon local pharmaceutics in vivo. Thus, distributive studies were repeated 
with MgP under conditions of full PEGylation, wherein Figure 4.7 highlights the modest increase in 
magnitude of draining lymphatic accumulation for PMP relative to PCP. It is valuable to note that while 
the differences are not of considerable statistical value, the effect size relative to traditional LCP remains 
improved and significant (9-fold vs. 6-fold). Further, in combination with an enhanced delivery of model 
oligonucleotide drug through the MgP over the CaP nanoparticle platform (Figure 4.8), MgP shows 
potential as a core platform which can salvage the immune response differential driven by the cationic 
lipid-mediated endosome escape of the traditional LCP. 
4.4.4: PMP Reconciles LCP Vaccine Response Absent Cationic Lipid 
 In order to explore the potential for competitive immune response  through a shift to MgP cores 
under full PEGylation, BALB/c mice, known to be reactive to the AH1-A5 antigen sequence,56 were 
vaccinated by subcutaneous injection of 40 and 8 µg respectively of pAH1-A5 peptide and adjuvant, as 
either free drug or encapsulated within PCP, PMP, or LCP. One week after vaccination, naïve mouse 
splenocytes were harvested and pulsed with either AH1 or β-gal peptides, the cells of which were 
respectively labeled with high or low concentrations of carboxyfluorescein to create distinct cell 
populations. Such cells were injected intravenously at a 1:1 ratio into the previously vaccinated mice (as 
well as untreated control), where after 18 hours the mice were sacrificed and their draining lymphocytes 
and splenocytes harvested for antigen-specific ELISpot and CTL analysis. ELISpot results reveal strong 
immune activation for all particle-based vaccine groups (Figure 4.9), while CTL results (Figure 4.10) 
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convey such impact on a more quantitative basis. At a dosing level wherein free antigen and adjuvant 
was ineffective, each particle-based vaccine yielded significant antigen-specific lysis; further, while the 
improved performance of LCP as compared with PCP remains readily apparent (52% vs. 31%, p < 0.02), 
the PMP nanosystem salvages almost entirely the magnitude of the LCP response (52% vs. 48%, p = 
0.60). Thus, PMP represents a competitive therapeutic modality to LCP in the context of antigen-specific 
immune activation in vivo. 
4.5: Discussion 
 Given the relatively small size of PCP nanoparticles overall, we considered that they may possess 
an enhanced lymphatic accumulation upon full PEGylation. Such hypotheses were largely driven by 
previous work with similarly-sized nanosystems, such as PEGylated dendrimers, which describe an 
improved lymphatic drainage not just in the scope of nanoparticle absorption rate, but in the cumulative 
exposure of nanoparticle, highlighting that extremely high PEGylation density serves to meaningfully 
reduce systemic exposure in favor of lymphatic drainage.54 Through a number of parallel observations 
herein, we observe exactly the same phenomenon: a considerable shift toward lymphatic localization 
for PCP over a more extensive systemic exposure for LCP, highlighting the distributive value for PCP as a 
lymphatically-focused delivery system. 
 Further, as PCP presented close to 1000% ID/gram accumulation within the local draining 
inguinal lymph node (in excess by 6-fold to that of LCP), we sought to parallel the promising results of 
hepatic delivery in the absence of cationic lipids described in the previous chapter by again establishing 
source conditions on the in vivo level. Under such logic, the premise exists again to endosomally insult 
cells with high concentrations of nanoparticle, such that osmotically-mediated endosome escape can be 
driven to therapeutically-relevant capacities. However, despite such strong distributive differences, PCP 
failed to outperform LCP in preliminary experiments, likely due to the weak internalization of both 
particle systems in comparison to alternative cell populations. Unlike the liver, to which such particles 
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are rapidly and predominantly distributed as well as readily and extensively internalized, the lymphatic 
accumulation represents a more cumulative and less aggressive distribution, not unlike that of systemic 
nanoparticle delivery to solid tumors, albeit reaching cumulative local exposures which are orders of 
magnitude in excess of that within such tumors. Thus, given a strong but gradual lymphatic distribution, 
we hypothesized that an enhanced capacity for endosome escape intrinsic to the liposomal 
nanoprecipitate could salvage the difference in immune response between the two systems. However, 
as in the case of systemic delivery, simply reintroducing cationic lipid into the fully-PEGylated platform 
represents an academically disinterested response to such conditions – of much greater value would be 
to improve intrinsic particle performance, thus allowing for a veritable mixing and matching of 
characteristics which can more ideally suit the needs of the endeavor at hand. 
 In this mindset, magnesium phosphate was considered as an alternative core nanoprecipitate, 
as its enhanced release characteristics and decreased propensity for aggregation couple with 
straightforward formulation and equitable drug encapsulation for the purposes of immune activation. 
With such ex vivo characteristics recapitulating in terms of extracellular and intracellular distributive 
profiles, it was not surprising to see a salvaged CTL response to the PMP vaccine in relation to LCP in 
vivo. Further, an obvious functional extension for both systems would be to either include MgP within 
the traditional 20 mol% PEGylated system (i.e. LMP) or include cationic cholesterol within the PMP 
system (e.g. PMP-DC), as both modifications may further improve therapeutic response; however, 
enhanced distribution through full PEGylation is shown to couple effectively with enhanced release 
through MgP to provide a competitive delivery platform for immune activation in vivo. 
4.6: Conclusions 
 Herein, we present the enhanced local delivery capabilities of such nanoparticles in vivo, 
focusing upon delivery to draining lymphatics upon subcutaneous injection. These PCP liposomes exhibit 
an enhanced accumulation within local lymph nodes which is largely driven by PEGylation density rather 
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than active targeting to immune cells, with absorption rate and systemic exposure differences 
underlying such expectations for improved lymphatic drainage. However, despite high distributive 
accumulation, limited internalization into cells through even active targeting strategies likely precludes 
comparable therapeutic effects in terms of measurable immune response. Therefore, we present a new 
derivative formulation based on the LCP nanoparticle platform, but instead utilizing magnesium 
phosphate as a nanoparticle core, which aims to resolve such limitations. These PMP nanoparticles 
exhibit a decreased propensity toward aggregation which contributes to an enhanced lymphatic 
distribution, as well as a more rapid rate of degradation at endosomal pH which can contribute to 
osmotic swelling and release therein. As such, PMP can effectively salvage formulation function in vivo 
in generating an antigen-specific, CTL-activating immune response. Thus, magnesium expands, along 
with calcium- and platinum-based nanoparticle cores, the library of potential pharmaceutic modalities 














Figure 4.1: LCP Biodistribution upon Subcutaneous Administration. LCP particles encapsulating trace 
177Lu were coated with either 100 mol% (PCP) or 20 mol% (LCP) DSPE-PEG2k and administered 
subcutaneously to BALB/c mice in 5% glucose (n = 3). Major organs were harvested at various time 
points and nanoparticle accumulation was determined radiometrically. C = contralateral, I = 















Figure 4.2: Systemic Particle Absorption after Subcutaneous Administration. LCP particles 
encapsulating trace 177Lu were coated with either 100 mol% (PCP) or 20 mol% (LCP) DSPE-PEG2k and 
administered subcutaneously to BALB/c mice in 10% sucrose (n = 3). After 72 hours, major organs 















Figure 4.3: Distribution and Absorption of LCP (Subcutaneous Administration). LCP particles 
encapsulating trace 177Lu were coated with either 100 mol% (PCP) or 20 mol% (LCP) DSPE-PEG2k and 
injected subcutaneously to BALB/c mice in 10% sucrose (n = 3). After 72 hours, major organs were 













Figure 4.4: Nanoparticle Size and Vaccine Encapsulation. LMP cores encapsulating peptide and oligo 



















Figure 4.5: LMP Stability. MgP cores were resuspended effectively with DSPE-PEG2000, stored at 4°C, 


















Figure 4.6: Drug Release is Enhanced in LMP vs. LCP. Nanoprecipitate liposomes comprising cores of 
either magnesium (LMP) or calcium (LCP) phosphate, encapsulating trace amounts of 177Lu were 
dialyzed against either 150mM pH 5.9 sodium citrate (5.9) or 150 mM pH 7.5 Tris-HCl (7.5) through a 
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Figure 4.7: PCP/PMP Biodistribution upon Subcutaneous Administration. Cores encapsulating trace 
177Lu were coated with 100 mol% DSPE-PEG2k and administered subcutaneously to BALB/c mice in 
5% glucose (n = 3). Major organs were harvested at various time points and nanoparticle 
















Figure 4.8: Cell Uptake of PCP and PMP. Nanoparticles encapsulating Texas Red-labeled oligonucleotide 
and targeted with mannose ligand were incubated with JAWS-II cells in vitro in complete medium for 2 














Figure 4.9: In Vivo Interferon Activation. AH1+CpG (40+8 µg) was injected s.c. into BALB/c mice. On 
day 7, draining inguinal lymph nodes and spleens were harvested into single cell suspensions and 
incubated for 18 hours in an antibody-coated plate at 1.25x105 cells per well. Interferon-gamma 



















Figure 4.10: In Vivo CTL Assay. AH1+CpG (40+8 µg) was injected s.c. into BALB/c mice (n=4). On day 7, 

















CHAPTER 5: SUMMARY AND FUTURE STUDIES 
5.1: Summary of Current Work 
 Herein, we extend the supported bilayer phenomenon to its maximal limits in spontaneous self-
assembly, presenting for the first time a liposome coated exclusively by PEGylated phospholipids. 
Utilizing lipid-coated calcium phosphate (CaP) and magnesium phosphate (MgP) as well as pure cisplatin 
(CDDP) cores of diverse sizes (10-40nm) as well as varying PEG chain lengths (350-5000 Da), we 
kinetically trap a relatively monodisperse nanoparticle population through simple solvent mixing in thin 
film rehydration, a process which is insufficient for non-exclusively PEGylated LCP suspension. Ex vivo 
experimentation highlights the ability for such formulations, particularly at increasing PEG chain lengths, 
to effectively screen nanoparticle surface charge and thus limit protein adsorption onto the nanoparticle 
and uptake of the nanoparticle into mononuclear phagocytes. Further, ratiometric characterization of 
the nanoparticle at a number of radial surfaces exposes the extremely high density of PEGylation which 
such nanoparticles can support, underscoring not only the equivalent lipid density to that of a traditional 
liposome bilayer, but the importance as well of aspect ratio in properly contextualizing the limits of 
spontaneous self-assembly. 
 Such fully-PEGylated (PCP, PMP, PPC as formulations employing calcium, magnesium, or 
platinum, respectively, within the nanoprecipitate core) liposomes allow us to explore a variety of 
hypotheses related to PEGylation density on a spontaneously self-assembled liposome surface for the 
first time. For instance, PCP exhibit a PEG chain length-dependent circulation longevity and robust 
immune evasion while resolving the rapid distribution clearance observed with the traditional LCP 
formulation and enhancing nanoparticle cellular internalization in commonly employed strategies of 
receptor-ligand targeting. Such liposomes advance the platforms’ pharmaceutics properties both locally 
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and systemically as well, facilitating both strong accumulation within solid tumors upon intravenous 
injection and a more rapid and extensive lymphatic drainage upon subcutaneous administration. Finally, 
when coupled with potent mechanisms of drug release, these fully-PEGylated liposomes reveal potent 
and competitive therapeutic activity in areas ranging from cancer chemotherapy to immune activation 
while limiting systemic toxicity overall. Thus, given the competitive flexibility and functionality of fully-
PEGylated liposome formulations through a maximally-supported lipid bilayer, we anticipate continued 
evolution of the formulation platform to support a variety of local and systemic diseases. 
5.2: Significance and Novelty of Current Work 
 Much time in this dissertation has been spent discussing the limits in formulation quality and 
potential for scalability of the traditional LCP nanoparticle platform. While such discussion is valid and 
relevant, it is intellectually important to note that such discussion is not to eliminate the possibility of 
successful scale-up of the traditional LCP formulation method – for instance, it should be obvious to 
anyone versed in the liposome development field that sonication is, at face value, a moderately scalable 
process. What is intended, however, is to bring to light the complications that are present, even today at 
bench-top scale, with numerous derivative formulations of the supported-bilayer nanoparticle platform. 
Given that we work and publish at an academic level of science, such a trial-and-error process in the 
relative “art” of nanoparticle resuspension is typically ignored in data generation and representation at 
the publication level – and rightly so! The purpose of the academic science generated therein is to 
highlight the extraordinary potential of such systems, not to off-handedly dismiss them for what in some 
instances would be esoteric criticisms. 
 However, given the long history of the supported-bilayer nanoprecipitates as a formulation 
platform, and persistent issues in formulation reproducibility, it becomes a relevant endeavor to not 
only design novel nanoparticle systems which offer strong in vivo pharmaceutics performance and 
therapeutic efficacy, but to consider the value of processes which are inherently less scale-limited at 
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face value. In that context, fully-PEGylated formulation represents a variety of simplified process 
considerations in contrast to the traditional LCP nanoparticle platform. Rather than careful preparation 
of a thin, transparent film through extensive manual intervention, full-PEGylation can achieve effective 
dispersion of nanoparticle cores without attention to this detail. To put it plainly, simply allowing the 
chloroform solution to dry under slow and steady nitrogen flow in a glass vial, without attending to 
exactly “how” the film dries on the vial, does not impede effective particle formation. Further, simple 
addition of absolute ethanol to the film, without mixing of any kind, is sufficient to resuspend the 
nanoparticles into a relatively homogenous dispersion (by visual inspection at minimum), lending the 
subsequent addition of an excess of water under simple mixing to be at face value strikingly translatable 
to more industrially-friendly solvent displacement and/or microfluidic process development (an 
interesting future engineering project in its own right!). Thus, even in the most conservative of 
assessments, the development of the fully-PEGylated, supported-bilayer nanoprecipitates serves to 
decrease risk and expand potential for translation of a highly capable formulation platform when 
benchmarked against its predecessor. One need only look at the recent suspension of Doxil production, 
due in large part to issues of batch-to-batch reproducibility, to see the value in developing a 
nanoparticle formulation which lends itself such potential. 
 While the density of the PEGylated surface on such fully-PEGylated, supported-bilayer 
nanoprecipitates remains intellectually interesting, it can be conservatively argued that such results are 
not entirely unexpected – arguments over aspect ratio which lend strength to the conclusions at hand 
also limit the potential scope of such formulation to a very specific type of liposomal nanoparticle. 
Further, despite valuable characterization of the formulation in comparison to the traditional LCP 
system, as well as in relationship to PEG chain length, the overall impact of the system to the field in 
terms of pharmaceutics properties is at best ‘functionally viable’ in comparison with highly dissimilar 
nanoparticle formulation strategies – for instance, in passive accumulation of such nanoparticles within 
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solid tumors,57, 58 or in enhancing circulation longevity.21, 59 Functionally, at least for delivery to solid 
tumors, the “bread-and-butter” of academic nanoparticle research for decades, passive nanoparticle 
accumulation within solid tumors can reasonably be expected to plateau at dose-normalized levels (i.e. 
equivalent injected dose per gram accumulating within tumor as compared to non-tumor clearing 
organs). Discussion of criticisms of the EPR effect to this end, as well as alternative applications for 
which full-PEGylation remains promising, will be considered in the next section, but suffice it to say at 
this point that the accumulation observed for the PCP platform (Figure 3.x) represents such a basic 
achievement, beyond which alternative means for efficacy must take hold. 
 What remains more striking, however, is the degree to which particular fully-PEGylated 
liposomal nanoparticles perform in the absence of cationic lipids. The reverse-hexagonal phase-based 
disruption of endosome membranes mediated by cationic lipids incorporated in nanoparticle 
formulations is a well-known mechanism through which to achieve endosome escape,6 and throughout 
the development of such nanoparticle systems, their potential carried the intrinsic and justifiable 
expectation that, therapeutically, they would struggle to outperform the traditional formulation. It can 
be argued that the fully-PEGylated system is also amenable to inclusion of cationic lipids, most obviously 
through the ionizable cholesterol analogue DC-Chol (Figure 2.5); further, a relatively sophomoric 
argument can be made about toxicity concerns with cationic lipids as well.6, 12 However, more profound 
value can be generated not in trying to simply create the most powerful nanoparticle one can, and 
publishing on those merits alone (which, to put it bluntly, everyone in the field does with their own 
“pet” nanoparticle systems anyway), but in exploring the potential for which these fully-PEGylated 
liposomes can perform in the absence of cationic lipids. Can they truly stand on their own? 
 What we’ve found is that exploitation of the nanoparticle core for performance enhancement 
can yield meaningful contributions to the in vivo efficacy of such formulation. For basic, proof-of-
concept models of nanoparticle delivery to solid tumors, wherein nanoparticle penetration into the 
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tumor bed is of only limited concern, the pure cisplatin cores utilized herein can be exploited for their 
profound bystander effect in a dual-functional capacity. First, should an uptake event occur, induced 
cytotoxicity has already been shown to facilitate a neighboring toxicity in previous work,31 and 
recapitulation of such enhanced toxicity in vitro is sufficient to represent such capabilities, albeit to a 
slightly lesser degree than through LPC (Figure 2.14). However, while such nanoparticles do not exhibit 
burst release, they do in fact slowly release cisplatin over time (Figure 3.x);31 therefore, simple 
accumulation of the nanoparticles within the tumor can facilitate strong effects at the proof-of-concept 
level as well (more complex tumor models will be discussed in the next section). Regarding lymphatic 
accumulation, given that the nanoparticle dose for subcutaneous vaccination is remarkably high (thus 
involving a high proportion of cationic lipids), and also given that lymphatic drainage is not inherently 
required for immune activation (i.e. antigen-presenting cell uptake of nanoparticle can obviously occur 
outside of formal lymphatic architecture), it would be naïve to expect immune activation problems to be 
easily solved through simple distribution enhancement. Thus, the selection of magnesium phosphate as 
an alternative core platform, shown both to limit nanoparticle aggregation potential as well as to 
enhance acid-sensitivity in controlled release (Figure 4.x), serves a similar performance benefit to that of 
cisplatin in delivery to solid tumors, representing a comparably powerful CTL activation under the fully-
PEGylated formulation conditions to traditional, cationic lipid-incorporating LCP (Figure 4.x). Therefore, 
it is argued herein that the performance benefits offered by cationic lipids are not insurmountable by 
alternative means, and that rational nanoparticle design at various levels of nanoparticle structure can 
serve functional in vivo efficacy. 
 LCP as a nanoparticle system has shown itself to be a relevant tool for a broad range of 
therapeutic and diagnostic modalities, ranging from radionuclide-based therapy60 and imaging,25 to gene 
silencing29 and transgene expression,26 to peptide27 and pro-drug28 delivery, and any combination in 
between, including with alternative liposomal nanoprecipitates such as cisplatin.31 What we have done 
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in this dissertation is not simply perform a side-by-side comparison of LCP versus full-PEGylation; to do 
so would lack meaningful intellectual value for the broader academic scientific community. These are 
the things industrially-focused follow-up is for. However, at this stage of development, full PEGylation 
appears to hold strong value in providing greatly simplified and comparably scale-unlimited formulation 
processes while maintaining performance across a diverse array of therapeutic modalities (gene 
expression, chemotherapy, immune activation). Further work will undoubtedly elucidate which methods 
perform best given the complexities of individual disease models, but to maintain performance against a 
mature nanoparticle system such as LCP remains no small feat. 
5.3: Future Expectations 
 Though foundational to nanoparticle delivery capabilities to solid tumors in vivo, the EPR effect 
has come under extensive criticism over the years,61-64 highlighting a variety of assumptions made by 
academic scientists in tumor model development. From a heightened interstitial fluid pressure within 
the core of the tumor which prevents deep nanoparticle penetration, to a stark variability in vascular 
permeability between models, to a reconsideration of the true magnitude of lymphatic retention 
present at the tumor periphery, the proof-of-concept models utilized in the studies herein should be 
taken for what they are intrinsically worth – an assessment of the potential of fully-PEGylated liposomes 
to achieve a basic therapeutic effect. They are most certainly not a panacea, in particular given recent 
work in assessment of their traversal of biological barriers along the path of delivery.32, 57, 62, 65 Given that 
accumulation of nanoparticles, even those sufficient to effectively penetrate traditional tissue 
interstitial, are confronted with a dense stromal barrier to delivery upon extravasation, the capabilities 
of simple chemotherapy strategies can be limited, and may even engender drug resistance through 
stroma-to-tumor signaling processes upon cytotoxic insult.32 Therefore, solutions must be developed 
which can overcome such limitations. One instance which has been presented is in using stromal 
delivery against the tumor itself, under a gene expression-based mechanism for tumor cell-specific 
135 
 
killing;32 indeed, such fully-PEGylated nanoparticles could be envisioned, under the correct design 
criteria, to perform effectively in this fashion. Nevertheless, much effort moving forward will be 
expected to harness the potential of nanotechnology as a means rather than as an end. 
  In this sense, specific advantages which nanotechnologies such as fully-PEGylated liposomes 
possess will likely emerge in a more targeted focus for therapeutic application, driving efforts to 
overcome a few (or even simply one) biological barriers rather than tackling the entire delivery modality 
through one system. Such fully-PEGylated liposomes represent a unique opportunity in intentional 
avenues of interstitial penetration in their own right, particularly through complex media such as 
mucus66 and brain tissue.67 Given their relatively small size (less than ~100 nm in diameter), high density 
of PEGylation (greater than ~0.1 PEG per square nm), and neutralized surface potential (between -5 and 
+5 mV, through incorporation of DC-Chol), fully-PEGylated liposomes hold strong potential for 
penetration as well as functional efficacy within the conditions previously defined for success within 
such biological barriers (Figure 5.1). Particularly for brain tissue penetration, convection-enhanced 
delivery (CED) represents an immediately-accessible and clinically-applicable mechanism, as the time-
scales of CED (on the order of minutes to hours for cubic millimeter- to centimeter-level penetration) 
frame well with the stability of the current cisplatin nanoprecipitate formulation. However, it must be 
noted that recent work also suggests nanoparticles of sufficiently small size (<70 nm) are not dependent 
upon PEG for unhindered transport under convection enhancement; therefore, the value of such full 
PEGylation may be by the relative ease of formulation as well as its intrinsic diffusivity.68  
 Multi-stage drug delivery has emerged in recent years to better tackle stepwise traversal of 
biological barriers,57, 58 and of particular interest is the potential of such strategies in combination with 
cell-mediated delivery.65 Facilitating active rather than passive targeting to sites of inflammation, as well 
as broad interstitial migration, cells are uniquely designed to overcome those specific biological barriers 
to tumor therapy which give such challenge to nanoparticle formulations, and while their intrinsic 
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capabilities in gene and protein expression may limit the utility of the nanotechnologies employed, 
efforts ranging from chemotherapy69-71 to nano-enzyme72 development have gained traction in recent 
years as a viable strategy for multistage formulation design, and have become competitive in efficacy 
with CED while avoiding the inconsistent and unfocused distribution which CED employs (Figure 5.2).70 
In this sense, continued formulation research may be driven on an architecturally-ignored area of the 
liposomal nanoprecipitates to date: the components of the inner lipid leaflet. A potential limitation of 
the cisplatin nanoparticle cores in such a strategy lies in their relative instability in comparison to LCP, 
despite an attractive 80% drug loading of cisplatin, yielding potential for untenable toxicity to the carrier 
cell. While the intrinsic bystander effect of such cisplatin nanoparticles remains attractive despite such 
concerns, it is striking to consider, however, that in each effort over countless publications on liposomal 
nanoprecipitates, the DOPA coating has been taken as an unquestioned given. Refocused efforts to 
enhance nanoparticle stability through a strengthened interface between core and bilayer (perhaps 
through an amine-bearing lipid-like molecule) could mediate profound stability benefits in such a multi-
stage delivery modality, thus advancing the scientific application of such supported-bilayer platforms 














Figure 5.1: NP Penetration of Brain Tissue In Vivo in Living Mice. (A) Direct comparison of the 
distribution of fluorescent NPs of similar sizes with different surface coatings after intracranial co-
injection into mice. Images were acquired 60 min after injection. Scale bars, 50 μm. (C) Representative 
particle trajectories for COOH- and PEG-coated NPs in live mouse brain. Trajectories shown are of 
particles that had an MSD equal to the ensemble average at a time scale of 1 s, as determined by at 








Figure 5.2: Schematic representation of NP delivery by stem cells within a brain tumor. A) Properties 
of NPs and stem cells for optimal combination. B) Before intratumoral injection, NPs should be 
incorporated into cells in vitro. C) Step-by-step delivery strategy: 1. Intratumoral injection of MSCs 
loaded with NPs into the tumor mass. 2. Migration of MSCs loaded with NPs. 3. MSC distribution at 
the border between normal brain parenchyma and the tumor mass, including tumor infiltrations. 4. 
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